[
  {
    "text": "As compared to the large number of secondary resistance mutations noted in acquired imatinib resistance in CML , in the case of EGFR-TK , there are currently only several documented resistance point mutations to gefitinib and erlotinib , including T790M , L747S and D761Y .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [212, 221],
        "tok_span": [37, 41]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [248, 253],
        "tok_span": [48, 52]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "gefitinib",
        "sbj_char_span": [248, 253],
        "obj_char_span": [212, 221],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [48, 52],
        "obj_tok_span": [37, 41]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "The magenta ball-stick ( located just above the gefitinib molecule in the active site ) indicates the gatekeeper residue ( threonine790 ) that is commonly mutated to methionine ( T790M ) , resulting in reduced inhibitor binding and drug resistance .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [48, 57],
        "tok_span": [11, 15]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [179, 184],
        "tok_span": [40, 44]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "gefitinib",
        "sbj_char_span": [179, 184],
        "obj_char_span": [48, 57],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [40, 44],
        "obj_tok_span": [11, 15]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "In cancer tissues from lung adenocarcinoma patients who showed resistance to gefitinib , high expression levels of HGF were observed in the lung cancer cells that did not harbor the T790M mutation or MET amplification .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [77, 86],
        "tok_span": [11, 15]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [182, 187],
        "tok_span": [34, 38]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "gefitinib",
        "sbj_char_span": [182, 187],
        "obj_char_span": [77, 86],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [34, 38],
        "obj_tok_span": [11, 15]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "To test this possibility , two types of gefitinib-sensitive cells ( PC9 cells that endogenously express EGFR deletion mutant in exon19 of EGFR gene and HEK293T cells that exogenously express EGFR L858R mutant ) were transfected with an expression vector encoding the oncogenic K-Ras G12V mutant .",
    "entity_list": [
      {
        "name": "gefitinib-sensitive",
        "ent_type": "drug",
        "char_span": [40, 59],
        "tok_span": [8, 14]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [196, 201],
        "tok_span": [42, 46]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "gefitinib-sensitive",
        "sbj_char_span": [196, 201],
        "obj_char_span": [40, 59],
        "rel_type": "sensitivity",
        "sbj_tok_span": [42, 46],
        "obj_tok_span": [8, 14]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "The T790M second mutation accounts for half of all resistances to gefitinib and erlotinib .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [66, 75],
        "tok_span": [15, 19]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [4, 9],
        "tok_span": [1, 5]
      },
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [80, 89],
        "tok_span": [20, 24]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "gefitinib",
        "sbj_char_span": [4, 9],
        "obj_char_span": [66, 75],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [1, 5],
        "obj_tok_span": [15, 19]
      },
      {
        "subject": "T790M",
        "object": "erlotinib",
        "sbj_char_span": [4, 9],
        "obj_char_span": [80, 89],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [1, 5],
        "obj_tok_span": [20, 24]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "NSCLC patients with exon 20 mutations showed a gefitinib response rate of 25 % , far lower than that of patients with exon 19 deletions and L858R mutations .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [47, 56],
        "tok_span": [8, 12]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [140, 145],
        "tok_span": [29, 33]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "gefitinib",
        "sbj_char_span": [140, 145],
        "obj_char_span": [47, 56],
        "rel_type": "sensitivity",
        "sbj_tok_span": [29, 33],
        "obj_tok_span": [8, 12]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "We also found gefitinib or NK cells could enhance MHC-I expression , which impairs the recognization of NK cells , in lung tumor cells with wild type EGFR , while not in those with EGFR L858R + T790M .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [14, 23],
        "tok_span": [3, 7]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [194, 199],
        "tok_span": [46, 50]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [186, 191],
        "tok_span": [41, 45]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "gefitinib",
        "sbj_char_span": [194, 199],
        "obj_char_span": [14, 23],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [46, 50],
        "obj_tok_span": [3, 7]
      },
      {
        "subject": "L858R",
        "object": "gefitinib",
        "sbj_char_span": [186, 191],
        "obj_char_span": [14, 23],
        "rel_type": "sensitivity",
        "sbj_tok_span": [41, 45],
        "obj_tok_span": [3, 7]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Therapeutic significance of our finding is that administration of gefitinib may offer a novel adjuvant strategy to enhance NK cells based immunotherapy in NSCLC with EGFR L858R + T790M resistance mutation .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [66, 75],
        "tok_span": [9, 13]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [179, 184],
        "tok_span": [34, 38]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [171, 176],
        "tok_span": [29, 33]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "gefitinib",
        "sbj_char_span": [179, 184],
        "obj_char_span": [66, 75],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [34, 38],
        "obj_tok_span": [9, 13]
      },
      {
        "subject": "L858R",
        "object": "gefitinib",
        "sbj_char_span": [171, 176],
        "obj_char_span": [66, 75],
        "rel_type": "sensitivity",
        "sbj_tok_span": [29, 33],
        "obj_tok_span": [9, 13]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "The investigated EGFR-TKI sensitive mutations included G719C , G719S , G719A , L858R , L861Q , and exon 19 deletions , as well as a gefitinib-resistant mutation , T790M .",
    "entity_list": [
      {
        "name": "gefitinib-resistant",
        "ent_type": "drug",
        "char_span": [132, 151],
        "tok_span": [43, 49]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [163, 168],
        "tok_span": [51, 55]
      },
      {
        "name": "G719S",
        "ent_type": "variant",
        "char_span": [63, 68],
        "tok_span": [14, 18]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [79, 84],
        "tok_span": [24, 28]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "gefitinib-resistant",
        "sbj_char_span": [163, 168],
        "obj_char_span": [132, 151],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [51, 55],
        "obj_tok_span": [43, 49]
      },
      {
        "subject": "G719S",
        "object": "gefitinib-resistant",
        "sbj_char_span": [63, 68],
        "obj_char_span": [132, 151],
        "rel_type": "sensitivity",
        "sbj_tok_span": [14, 18],
        "obj_tok_span": [43, 49]
      },
      {
        "subject": "L858R",
        "object": "gefitinib-resistant",
        "sbj_char_span": [79, 84],
        "obj_char_span": [132, 151],
        "rel_type": "sensitivity",
        "sbj_tok_span": [24, 28],
        "obj_tok_span": [43, 49]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "In gefitinib treated patients , six EGFR mutations involved exon 19 deletions that lacked the amino acids Leu-Arg-Glu-Ala , and two were exon 21 amino acid substitutions ( L858R ) .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [3, 12],
        "tok_span": [1, 5]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [172, 177],
        "tok_span": [37, 41]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "gefitinib",
        "sbj_char_span": [172, 177],
        "obj_char_span": [3, 12],
        "rel_type": "sensitivity",
        "sbj_tok_span": [37, 41],
        "obj_tok_span": [1, 5]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "The EGF receptor tyrosine kinase inhibitors ( EGFR-TKIs ) gefitinib and erlotinib have shown marked therapeutic effects against NSCLCs with EGFR activating mutations , such as exon 19 deletions and L858R point mutations . ",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [58, 67],
        "tok_span": [12, 16]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [198, 203],
        "tok_span": [40, 44]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "gefitinib",
        "sbj_char_span": [198, 203],
        "obj_char_span": [58, 67],
        "rel_type": "sensitivity",
        "sbj_tok_span": [40, 44],
        "obj_tok_span": [12, 16]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Recently a new EGFR mutation of T790M was discovered that explained the resistance to gefitinib after drug administration .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [86, 95],
        "tok_span": [17, 21]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [32, 37],
        "tok_span": [6, 10]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "gefitinib",
        "sbj_char_span": [32, 37],
        "obj_char_span": [86, 95],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [6, 10],
        "obj_tok_span": [17, 21]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Two EGFR mutations ( exon 19 deletion and exon 21 L858R substitution ) that cluster around the adenosine-5′-triphosphate binding pocket of the EGFR tyrosine kinase ( TK ) domain are highly responsive to EGFR TK inhibitors ( TKIs ) like gefitinib or erlotinib .",
    "entity_list": [
      {
        "name": "like gefitinib",
        "ent_type": "drug",
        "char_span": [231, 245],
        "tok_span": [52, 57]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [50, 55],
        "tok_span": [10, 14]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "like gefitinib",
        "sbj_char_span": [50, 55],
        "obj_char_span": [231, 245],
        "rel_type": "sensitivity",
        "sbj_tok_span": [10, 14],
        "obj_tok_span": [52, 57]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "MiR-200c could upregulate the expression of E-cadherin and trigger MET in H1975 , but can not reverse the resistance to gefitinib owing to T790M existence .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [120, 129],
        "tok_span": [31, 35]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [139, 144],
        "tok_span": [37, 41]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "gefitinib",
        "sbj_char_span": [139, 144],
        "obj_char_span": [120, 129],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [37, 41],
        "obj_tok_span": [31, 35]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "The Spanish Lung Cancer Group screened 2105 patients , to identify 350 patients ( 15 % ) with exon 19 deletions and L858R of whom 250 patients went on to receive erlotinib in the first or second-line setting . ",
    "entity_list": [
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [116, 121],
        "tok_span": [23, 27]
      },
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [162, 171],
        "tok_span": [35, 39]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "erlotinib",
        "sbj_char_span": [116, 121],
        "obj_char_span": [162, 171],
        "rel_type": "sensitivity",
        "sbj_tok_span": [23, 27],
        "obj_tok_span": [35, 39]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "The most common mechanism of acquired drug resistance gefitinib is the secondary EGFR T790M mutation , which is detected in up to 60 % of EGFR mutant NSCLC patients .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [54, 63],
        "tok_span": [8, 12]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [86, 91],
        "tok_span": [16, 20]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "gefitinib",
        "sbj_char_span": [86, 91],
        "obj_char_span": [54, 63],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [16, 20],
        "obj_tok_span": [8, 12]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Cases Age ( yr ) Sex PS Histology EGFR gene Smoking status Previous chemotherapy regimen Previous gefitinib ( length of PFS ) Previous WBRT 1 59 F 3 Ad NE Never 3 Yes ( 10 months ) Yes 2 82 F 4 Ad Wild type Never 0 No No 3 70 F 3 Ad Wild type Never 1 No Yes 4 86 F 3 Ad Ex 21 ; L858R Never 1 Yes ( 7 months ) No 5 67 F 1 Ad Ex 21 ; L858R Never 1 No No 6 72 M 0 Ad Ex 21 ; L858R Former 1 No No 7 81 M 1 Ad Ex 19 deletion Former 1 Yes ( 46 months ) Yes 8 85 F 2 Ad Ex 21 ; L858R Never 1 No Yes a 66 F 1 Ad Ex 21 ; L858R Never 3 No Yes",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [98, 107],
        "tok_span": [18, 22]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [278, 283],
        "tok_span": [74, 78]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "gefitinib",
        "sbj_char_span": [278, 283],
        "obj_char_span": [98, 107],
        "rel_type": "sensitivity",
        "sbj_tok_span": [74, 78],
        "obj_tok_span": [18, 22]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "In the IRESSA Pan-Asia Study ( IPASS ) study , eleven treatment-naïve patients had an exon 20 T790M mutation : four had coexisting exon 19 deletions and three had coexisting L858R mutations .",
    "entity_list": [
      {
        "name": "IRESSA",
        "ent_type": "drug",
        "char_span": [7, 13],
        "tok_span": [2, 5]
      },
      {
        "name": "20 T790M",
        "ent_type": "variant",
        "char_span": [91, 99],
        "tok_span": [23, 28]
      },
      {
        "name": "coexisting L858R",
        "ent_type": "variant",
        "char_span": [163, 179],
        "tok_span": [40, 46]
      }
    ],
    "relation_list": [
      {
        "subject": "20 T790M",
        "object": "IRESSA",
        "sbj_char_span": [91, 99],
        "obj_char_span": [7, 13],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [23, 28],
        "obj_tok_span": [2, 5]
      },
      {
        "subject": "coexisting L858R",
        "object": "IRESSA",
        "sbj_char_span": [163, 179],
        "obj_char_span": [7, 13],
        "rel_type": "sensitivity",
        "sbj_tok_span": [40, 46],
        "obj_tok_span": [2, 5]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "This molecular change had been found in samples with gefitinib or erlotinib resistance in vivo or in vitro . c-MET amplification has also occasionally been found to coexist with EGFR T790M mutation .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [53, 62],
        "tok_span": [9, 13]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [183, 188],
        "tok_span": [39, 43]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "gefitinib",
        "sbj_char_span": [183, 188],
        "obj_char_span": [53, 62],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [39, 43],
        "obj_tok_span": [9, 13]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "In contrast , YFP-EGFR-ICD L858R induced phosphorylation of endogenous Akt , which was inhibited by 10 nM of erlotinib , and 100 nM or higher concentrations of the drug induced fibril formation .",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [109, 118],
        "tok_span": [26, 30]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [27, 32],
        "tok_span": [9, 13]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "erlotinib",
        "sbj_char_span": [27, 32],
        "obj_char_span": [109, 118],
        "rel_type": "sensitivity",
        "sbj_tok_span": [9, 13],
        "obj_tok_span": [26, 30]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "The T790M mutation abrogated the effect of erlotinib on L858R , and the L858R/T790M double mutant readily induced Akt phosphorylation even in the presence of 10 μM erlotinib .",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [43, 52],
        "tok_span": [12, 16]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [56, 61],
        "tok_span": [17, 21]
      },
      {
        "name": "μM erlotinib",
        "ent_type": "drug",
        "char_span": [161, 173],
        "tok_span": [45, 51]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [4, 9],
        "tok_span": [1, 5]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "erlotinib",
        "sbj_char_span": [56, 61],
        "obj_char_span": [43, 52],
        "rel_type": "sensitivity",
        "sbj_tok_span": [17, 21],
        "obj_tok_span": [12, 16]
      },
      {
        "subject": "L858R",
        "object": "μM erlotinib",
        "sbj_char_span": [56, 61],
        "obj_char_span": [161, 173],
        "rel_type": "sensitivity",
        "sbj_tok_span": [17, 21],
        "obj_tok_span": [45, 51]
      },
      {
        "subject": "T790M",
        "object": "erlotinib",
        "sbj_char_span": [4, 9],
        "obj_char_span": [43, 52],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [1, 5],
        "obj_tok_span": [12, 16]
      },
      {
        "subject": "T790M",
        "object": "μM erlotinib",
        "sbj_char_span": [4, 9],
        "obj_char_span": [161, 173],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [1, 5],
        "obj_tok_span": [45, 51]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "In this regard , certain mutations , such as the T790M amino acid change , have been shown to confer resistance to gefitinib and erlotinib ] .",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [129, 138],
        "tok_span": [30, 34]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [49, 54],
        "tok_span": [10, 14]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "erlotinib",
        "sbj_char_span": [49, 54],
        "obj_char_span": [129, 138],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [10, 14],
        "obj_tok_span": [30, 34]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Transformation induced by expression of L858R , G719S , and L747_E749del A750P EGFR , but not EGF stimulated wild-type EGFR or D770_N771insNPG EGFR , was inhibited by 0.1 μM erlotinib .",
    "entity_list": [
      {
        "name": "μM erlotinib",
        "ent_type": "drug",
        "char_span": [171, 183],
        "tok_span": [57, 63]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [40, 45],
        "tok_span": [5, 9]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "μM erlotinib",
        "sbj_char_span": [40, 45],
        "obj_char_span": [171, 183],
        "rel_type": "sensitivity",
        "sbj_tok_span": [5, 9],
        "obj_tok_span": [57, 63]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Moreover , the second-generation irreversible EGFR inhibitors were shown in preclinical models to be more potent targeting T790M mutation than gefitinib or erlotinib .",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [156, 165],
        "tok_span": [30, 34]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [123, 128],
        "tok_span": [19, 23]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "erlotinib",
        "sbj_char_span": [123, 128],
        "obj_char_span": [156, 165],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [19, 23],
        "obj_tok_span": [30, 34]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "One of the mutations ( L858R ) was previously identified in non-small cell lung cancer ( NSCLC ) patients and this mutation was found to increase sensitivity to EGFR inhibitor , Erlotinib .",
    "entity_list": [
      {
        "name": "Erlotinib",
        "ent_type": "drug",
        "char_span": [178, 187],
        "tok_span": [36, 39]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [23, 28],
        "tok_span": [5, 9]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "Erlotinib",
        "sbj_char_span": [23, 28],
        "obj_char_span": [178, 187],
        "rel_type": "sensitivity",
        "sbj_tok_span": [5, 9],
        "obj_tok_span": [36, 39]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "The cell line H1975 has a sensitizing L858R kinase domain mutation in exon 21 , but also a second mutation ( T790M , in cis , in the kinase domain ) rendering them resistant to the reversible TKIs gefitinib and erlotinib .",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [211, 220],
        "tok_span": [53, 57]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [38, 43],
        "tok_span": [10, 14]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [109, 114],
        "tok_span": [27, 31]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "erlotinib",
        "sbj_char_span": [38, 43],
        "obj_char_span": [211, 220],
        "rel_type": "sensitivity",
        "sbj_tok_span": [10, 14],
        "obj_tok_span": [53, 57]
      },
      {
        "subject": "T790M",
        "object": "erlotinib",
        "sbj_char_span": [109, 114],
        "obj_char_span": [211, 220],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [27, 31],
        "obj_tok_span": [53, 57]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Afatinib was more potent than gefitinib , erlotinib , and lapatinib in inducing the cell death of NSCLC cell lines , including those harboring wild-type EGFR , and the erlotinib-resistant T790M mutation .",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [42, 51],
        "tok_span": [11, 15]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [188, 193],
        "tok_span": [46, 50]
      },
      {
        "name": "erlotinib-resistant",
        "ent_type": "drug",
        "char_span": [168, 187],
        "tok_span": [40, 46]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "erlotinib",
        "sbj_char_span": [188, 193],
        "obj_char_span": [42, 51],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [46, 50],
        "obj_tok_span": [11, 15]
      },
      {
        "subject": "T790M",
        "object": "erlotinib-resistant",
        "sbj_char_span": [188, 193],
        "obj_char_span": [168, 187],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [46, 50],
        "obj_tok_span": [40, 46]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Epidermal growth factor receptor (EGFR) activating mutations , such as exon 19 deletion and exon 21 L858R point mutation , are found in a population of NSCLC , and are associated with a clinical response to the EGFR tyrosine kinase inhibitors ( EGF-TKIs ) , gefitinib and erlotinib – .",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [272, 281],
        "tok_span": [59, 63]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [100, 105],
        "tok_span": [19, 23]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "erlotinib",
        "sbj_char_span": [100, 105],
        "obj_char_span": [272, 281],
        "rel_type": "sensitivity",
        "sbj_tok_span": [19, 23],
        "obj_tok_span": [59, 63]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Transient transfection experiments utilizing COS-7 cells demonstrated that auto-phosphorylation of the original L858R EGFR was inhibited by lower concentrations of gefitinib or erlotinib than the L858R-L747S or L858R-T790M constructs ( A ) . ",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [177, 186],
        "tok_span": [33, 37]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [112, 117],
        "tok_span": [17, 21]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "erlotinib",
        "sbj_char_span": [112, 117],
        "obj_char_span": [177, 186],
        "rel_type": "sensitivity",
        "sbj_tok_span": [17, 21],
        "obj_tok_span": [33, 37]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Activating mutations such as exon 21 missense point mutation L858R and in-frame deletions in exon 19 are the most commonly studied predictive biomarkers of response to EGFR-TKIs ( gefitinib and erlotinib ) , . ",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [194, 203],
        "tok_span": [43, 47]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [61, 66],
        "tok_span": [11, 15]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "erlotinib",
        "sbj_char_span": [61, 66],
        "obj_char_span": [194, 203],
        "rel_type": "sensitivity",
        "sbj_tok_span": [11, 15],
        "obj_tok_span": [43, 47]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "A non-small-cell lung cancer cell line bearing both T790M and L858R mutations was approximately 100-fold less sensitive to gefitinib or erlotinib , and did not show inhibition of tyrosine phosphorylation in vitro .",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [136, 145],
        "tok_span": [35, 39]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [62, 67],
        "tok_span": [17, 21]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [52, 57],
        "tok_span": [12, 16]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "erlotinib",
        "sbj_char_span": [62, 67],
        "obj_char_span": [136, 145],
        "rel_type": "sensitivity",
        "sbj_tok_span": [17, 21],
        "obj_tok_span": [35, 39]
      },
      {
        "subject": "T790M",
        "object": "erlotinib",
        "sbj_char_span": [52, 57],
        "obj_char_span": [136, 145],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [12, 16],
        "obj_tok_span": [35, 39]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "The research article by Pao et al. provides important new information addressing three patients with acquired resistance to gefitinib or erlotinib in progressing tumors containing a secondary mutation , leading to the substitution of methionine for threonine at position 790 ( T790M ) in exon 20 .",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [137, 146],
        "tok_span": [25, 29]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [277, 282],
        "tok_span": [52, 56]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "erlotinib",
        "sbj_char_span": [277, 282],
        "obj_char_span": [137, 146],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [52, 56],
        "obj_tok_span": [25, 29]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Colon-cancer derived G719S and G724S mutants are oncogenic and sensitive to cetuximab",
    "entity_list": [
      {
        "name": "cetuximab",
        "ent_type": "drug",
        "char_span": [76, 85],
        "tok_span": [19, 23]
      },
      {
        "name": "G719S",
        "ent_type": "variant",
        "char_span": [21, 26],
        "tok_span": [4, 8]
      },
      {
        "name": "G724S",
        "ent_type": "variant",
        "char_span": [31, 36],
        "tok_span": [9, 13]
      }
    ],
    "relation_list": [
      {
        "subject": "G719S",
        "object": "cetuximab",
        "sbj_char_span": [21, 26],
        "obj_char_span": [76, 85],
        "rel_type": "sensitivity",
        "sbj_tok_span": [4, 8],
        "obj_tok_span": [19, 23]
      },
      {
        "subject": "G724S",
        "object": "cetuximab",
        "sbj_char_span": [31, 36],
        "obj_char_span": [76, 85],
        "rel_type": "sensitivity",
        "sbj_tok_span": [9, 13],
        "obj_tok_span": [19, 23]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "In order to further examine the efficacy of cetuximab , we expanded our studies by generating xenograft mouse models with either SW48 or HCT8 colon cancer cells , which harbor either EGFR G719S or KRAS G13D mutation , respectively .",
    "entity_list": [
      {
        "name": "cetuximab",
        "ent_type": "drug",
        "char_span": [44, 53],
        "tok_span": [8, 12]
      },
      {
        "name": "G719S",
        "ent_type": "variant",
        "char_span": [188, 193],
        "tok_span": [38, 42]
      },
      {
        "name": "G13D",
        "ent_type": "variant",
        "char_span": [202, 206],
        "tok_span": [45, 48]
      }
    ],
    "relation_list": [
      {
        "subject": "G719S",
        "object": "cetuximab",
        "sbj_char_span": [188, 193],
        "obj_char_span": [44, 53],
        "rel_type": "sensitivity",
        "sbj_tok_span": [38, 42],
        "obj_tok_span": [8, 12]
      },
      {
        "subject": "G13D",
        "object": "cetuximab",
        "sbj_char_span": [202, 206],
        "obj_char_span": [44, 53],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [45, 48],
        "obj_tok_span": [8, 12]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "B ) , suggesting the anti-tumor effect of cetuximab against tumors harboring EGFR G719S mutant .",
    "entity_list": [
      {
        "name": "cetuximab",
        "ent_type": "drug",
        "char_span": [42, 51],
        "tok_span": [10, 14]
      },
      {
        "name": "G719S",
        "ent_type": "variant",
        "char_span": [82, 87],
        "tok_span": [18, 22]
      }
    ],
    "relation_list": [
      {
        "subject": "G719S",
        "object": "cetuximab",
        "sbj_char_span": [82, 87],
        "obj_char_span": [42, 51],
        "rel_type": "sensitivity",
        "sbj_tok_span": [18, 22],
        "obj_tok_span": [10, 14]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Taken together , these data suggest that colon cancer derived cetuximab-sensitive G719S and G724S mutants acquire their oncogenic potentials following asymmetric dimerization , respectively , which are similar to lung-cancer derived L858R mutant .",
    "entity_list": [
      {
        "name": "cetuximab-sensitive",
        "ent_type": "drug",
        "char_span": [62, 81],
        "tok_span": [10, 16]
      },
      {
        "name": "G719S",
        "ent_type": "variant",
        "char_span": [82, 87],
        "tok_span": [16, 20]
      },
      {
        "name": "G724S",
        "ent_type": "variant",
        "char_span": [92, 97],
        "tok_span": [21, 25]
      }
    ],
    "relation_list": [
      {
        "subject": "G719S",
        "object": "cetuximab-sensitive",
        "sbj_char_span": [82, 87],
        "obj_char_span": [62, 81],
        "rel_type": "sensitivity",
        "sbj_tok_span": [16, 20],
        "obj_tok_span": [10, 16]
      },
      {
        "subject": "G724S",
        "object": "cetuximab-sensitive",
        "sbj_char_span": [92, 97],
        "obj_char_span": [62, 81],
        "rel_type": "sensitivity",
        "sbj_tok_span": [21, 25],
        "obj_tok_span": [10, 16]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Furthermore , we found that dimerization dependent L858R mutant shows a dramatic response to cetuximab , whereas tumors driven by dimerization independent mutants such as T790M are resistant to the antibody , suggesting that there is a close correlation between dimerization dependency of lung cancer derived oncogenic mutant EGFR and pharmacological effects of cetuximab .",
    "entity_list": [
      {
        "name": "cetuximab",
        "ent_type": "drug",
        "char_span": [93, 102],
        "tok_span": [18, 22]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [171, 176],
        "tok_span": [33, 37]
      },
      {
        "name": "cetuximab",
        "ent_type": "drug",
        "char_span": [362, 371],
        "tok_span": [65, 69]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "cetuximab",
        "sbj_char_span": [171, 176],
        "obj_char_span": [93, 102],
        "rel_type": "response",
        "sbj_tok_span": [33, 37],
        "obj_tok_span": [18, 22]
      },
      {
        "subject": "T790M",
        "object": "cetuximab",
        "sbj_char_span": [171, 176],
        "obj_char_span": [362, 371],
        "rel_type": "response",
        "sbj_tok_span": [33, 37],
        "obj_tok_span": [65, 69]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Recently , the addition of cetuximab to afatinib has yielded impressive results in the treatment of EGFR reversible TKI resistant lung cancer due to T790M mutation .",
    "entity_list": [
      {
        "name": "cetuximab",
        "ent_type": "drug",
        "char_span": [27, 36],
        "tok_span": [5, 9]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [149, 154],
        "tok_span": [29, 33]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "cetuximab",
        "sbj_char_span": [149, 154],
        "obj_char_span": [27, 36],
        "rel_type": "response",
        "sbj_tok_span": [29, 33],
        "obj_tok_span": [5, 9]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Acquired resistance EGFR mutations Mutations in the EC domain ( S492R ) and in the kinase domain ( codons 714 and 794 ) of EGFR found in patients Panitumumab remained active in a patient with S492R mutation , which abrogated cetuximab binding .",
    "entity_list": [
      {
        "name": "cetuximab",
        "ent_type": "drug",
        "char_span": [225, 234],
        "tok_span": [53, 57]
      },
      {
        "name": "S492R",
        "ent_type": "variant",
        "char_span": [64, 69],
        "tok_span": [11, 15]
      }
    ],
    "relation_list": [
      {
        "subject": "S492R",
        "object": "cetuximab",
        "sbj_char_span": [64, 69],
        "obj_char_span": [225, 234],
        "rel_type": "resistance",
        "sbj_tok_span": [11, 15],
        "obj_tok_span": [53, 57]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "The BRAF V600E mutation has been described as a predictor of tumor aggressiveness in metastatic disease and also of low RRs to cetuximab and panitumumab .",
    "entity_list": [
      {
        "name": "cetuximab",
        "ent_type": "drug",
        "char_span": [127, 136],
        "tok_span": [26, 30]
      },
      {
        "name": "V600E",
        "ent_type": "variant",
        "char_span": [9, 14],
        "tok_span": [2, 5]
      }
    ],
    "relation_list": [
      {
        "subject": "V600E",
        "object": "cetuximab",
        "sbj_char_span": [9, 14],
        "obj_char_span": [127, 136],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [2, 5],
        "obj_tok_span": [26, 30]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "The effect of BRAF V600E mutation on cetuximab or panitumumab response was also assessed using cellular models of CRC .",
    "entity_list": [
      {
        "name": "cetuximab",
        "ent_type": "drug",
        "char_span": [37, 46],
        "tok_span": [9, 13]
      },
      {
        "name": "V600E",
        "ent_type": "variant",
        "char_span": [19, 24],
        "tok_span": [4, 7]
      }
    ],
    "relation_list": [
      {
        "subject": "V600E",
        "object": "cetuximab",
        "sbj_char_span": [19, 24],
        "obj_char_span": [37, 46],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [4, 7],
        "obj_tok_span": [9, 13]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "The introduction of BRAF V600E allele impaired the therapeutic effect of cetuximab or panitumumab .",
    "entity_list": [
      {
        "name": "cetuximab",
        "ent_type": "drug",
        "char_span": [73, 82],
        "tok_span": [13, 17]
      },
      {
        "name": "V600E",
        "ent_type": "variant",
        "char_span": [25, 30],
        "tok_span": [4, 7]
      }
    ],
    "relation_list": [
      {
        "subject": "V600E",
        "object": "cetuximab",
        "sbj_char_span": [25, 30],
        "obj_char_span": [73, 82],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [4, 7],
        "obj_tok_span": [13, 17]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "In the one case of discordance between KRAS mutation status before and after combined cetuximab therapy ( case # 4 ) , a mutated KRAS gene ( Exon 2 G12D ) was found in the primary CRC , while no KRAS mutation was observed in a liver metastasis sample obtained after combined cetuximab therapy ( ) .",
    "entity_list": [
      {
        "name": "cetuximab",
        "ent_type": "drug",
        "char_span": [86, 95],
        "tok_span": [16, 20]
      },
      {
        "name": "G12D",
        "ent_type": "variant",
        "char_span": [148, 152],
        "tok_span": [36, 39]
      },
      {
        "name": "cetuximab",
        "ent_type": "drug",
        "char_span": [275, 284],
        "tok_span": [62, 66]
      }
    ],
    "relation_list": [
      {
        "subject": "G12D",
        "object": "cetuximab",
        "sbj_char_span": [148, 152],
        "obj_char_span": [86, 95],
        "rel_type": "sensitivity",
        "sbj_tok_span": [36, 39],
        "obj_tok_span": [16, 20]
      },
      {
        "subject": "G12D",
        "object": "cetuximab",
        "sbj_char_span": [148, 152],
        "obj_char_span": [275, 284],
        "rel_type": "sensitivity",
        "sbj_tok_span": [36, 39],
        "obj_tok_span": [62, 66]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Furthermore , although KRAS mutations are typically associated with non-responsiveness to anti-EGFR antibodies , recent data indicate that KRAS G13D mutations may be a positive predictor of cetuximab response .",
    "entity_list": [
      {
        "name": "cetuximab",
        "ent_type": "drug",
        "char_span": [190, 199],
        "tok_span": [35, 39]
      },
      {
        "name": "G13D",
        "ent_type": "variant",
        "char_span": [144, 148],
        "tok_span": [25, 28]
      }
    ],
    "relation_list": [
      {
        "subject": "G13D",
        "object": "cetuximab",
        "sbj_char_span": [144, 148],
        "obj_char_span": [190, 199],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [25, 28],
        "obj_tok_span": [35, 39]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "The D842V was identified in one patient with primary mutation V561D , which is known to be associated with imatinib resistance .",
    "entity_list": [
      {
        "name": "imatinib",
        "ent_type": "drug",
        "char_span": [107, 115],
        "tok_span": [25, 27]
      },
      {
        "name": "D842V",
        "ent_type": "variant",
        "char_span": [4, 9],
        "tok_span": [1, 5]
      }
    ],
    "relation_list": [
      {
        "subject": "D842V",
        "object": "imatinib",
        "sbj_char_span": [4, 9],
        "obj_char_span": [107, 115],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [1, 5],
        "obj_tok_span": [25, 27]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Whenever possible , mutational analysis is suggested for identifying a baseline mutation and the presence of PDGFRA D842V mutation , which is known to be resistant to imatinib .",
    "entity_list": [
      {
        "name": "imatinib",
        "ent_type": "drug",
        "char_span": [167, 175],
        "tok_span": [32, 34]
      },
      {
        "name": "D842V",
        "ent_type": "variant",
        "char_span": [116, 121],
        "tok_span": [19, 23]
      }
    ],
    "relation_list": [
      {
        "subject": "D842V",
        "object": "imatinib",
        "sbj_char_span": [116, 121],
        "obj_char_span": [167, 175],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [19, 23],
        "obj_tok_span": [32, 34]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Additionally , AP26113 was evaluated on the crizotinib resistant gatekeeper mutant L1196M both in vitro and in vivo and appeared to be able to overcome resistance to crizotinib .",
    "entity_list": [
      {
        "name": "crizotinib",
        "ent_type": "drug",
        "char_span": [44, 54],
        "tok_span": [9, 13]
      },
      {
        "name": "L1196M",
        "ent_type": "variant",
        "char_span": [83, 89],
        "tok_span": [18, 22]
      },
      {
        "name": "crizotinib",
        "ent_type": "drug",
        "char_span": [166, 176],
        "tok_span": [37, 41]
      }
    ],
    "relation_list": [
      {
        "subject": "L1196M",
        "object": "crizotinib",
        "sbj_char_span": [83, 89],
        "obj_char_span": [44, 54],
        "rel_type": "resistance",
        "sbj_tok_span": [18, 22],
        "obj_tok_span": [9, 13]
      },
      {
        "subject": "L1196M",
        "object": "crizotinib",
        "sbj_char_span": [83, 89],
        "obj_char_span": [166, 176],
        "rel_type": "resistance",
        "sbj_tok_span": [18, 22],
        "obj_tok_span": [37, 41]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Afatinib is an orally , irreversible EGFR , HER2 and HER4 inhibitor , showing preclinical activity against cancer cells harboring common activating EGFR mutations and the T790M mutation , albeit with a lower potency .",
    "entity_list": [
      {
        "name": "Afatinib",
        "ent_type": "drug",
        "char_span": [0, 8],
        "tok_span": [0, 2]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [171, 176],
        "tok_span": [29, 33]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "Afatinib",
        "sbj_char_span": [171, 176],
        "obj_char_span": [0, 8],
        "rel_type": "response",
        "sbj_tok_span": [29, 33],
        "obj_tok_span": [0, 2]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Afatinib also shows activity against cancers resistant to first-generation EGFR inhibitors due to certain activating EGFR mutations , secondary EGFR mutations such as T790M or tumours expressing other ErbB family receptors activated by drug induced reprogramming of signalling pathways .",
    "entity_list": [
      {
        "name": "Afatinib",
        "ent_type": "drug",
        "char_span": [0, 8],
        "tok_span": [0, 2]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [167, 172],
        "tok_span": [26, 30]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "Afatinib",
        "sbj_char_span": [167, 172],
        "obj_char_span": [0, 8],
        "rel_type": "response",
        "sbj_tok_span": [26, 30],
        "obj_tok_span": [0, 2]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "In vitro studies and some case reports have shown that afatinib is effective ( cell apoptosis and disease stabilisation ) in cells harbouring the T790M mutation in NSCLC patients .",
    "entity_list": [
      {
        "name": "afatinib",
        "ent_type": "drug",
        "char_span": [55, 63],
        "tok_span": [10, 12]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [146, 151],
        "tok_span": [28, 32]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "afatinib",
        "sbj_char_span": [146, 151],
        "obj_char_span": [55, 63],
        "rel_type": "response",
        "sbj_tok_span": [28, 32],
        "obj_tok_span": [10, 12]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Another approach for T790M mediated resistance is the dual inhibition of EGFR with afatinib and cetuximab , an EGFR blocking antibody resembling the synergistic combination of lapatinib and trastuzumab in ErbB2 positive breast cancer .",
    "entity_list": [
      {
        "name": "afatinib",
        "ent_type": "drug",
        "char_span": [83, 91],
        "tok_span": [16, 18]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [21, 26],
        "tok_span": [3, 7]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "afatinib",
        "sbj_char_span": [21, 26],
        "obj_char_span": [83, 91],
        "rel_type": "response",
        "sbj_tok_span": [3, 7],
        "obj_tok_span": [16, 18]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Combination therapy with dasatinib and low-dose decitabine in TET2 mutated SM Next , we exploited the cooperation between loss of function of TET2 and KIT D816V in the HMC-1.2 cell line to validate possible combinatorial approaches to treatment for ASM and MCL , .",
    "entity_list": [
      {
        "name": "dasatinib",
        "ent_type": "drug",
        "char_span": [25, 34],
        "tok_span": [4, 6]
      },
      {
        "name": "D816V",
        "ent_type": "variant",
        "char_span": [155, 160],
        "tok_span": [37, 41]
      }
    ],
    "relation_list": [
      {
        "subject": "D816V",
        "object": "dasatinib",
        "sbj_char_span": [155, 160],
        "obj_char_span": [25, 34],
        "rel_type": "response",
        "sbj_tok_span": [37, 41],
        "obj_tok_span": [4, 6]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "( C ) Ba/F3 T315I cells were cultured in the presence of varying concentrations of ponatinib for 72 h .",
    "entity_list": [
      {
        "name": "ponatinib",
        "ent_type": "drug",
        "char_span": [83, 92],
        "tok_span": [21, 25]
      },
      {
        "name": "T315I",
        "ent_type": "variant",
        "char_span": [12, 17],
        "tok_span": [7, 11]
      }
    ],
    "relation_list": [
      {
        "subject": "T315I",
        "object": "ponatinib",
        "sbj_char_span": [12, 17],
        "obj_char_span": [83, 92],
        "rel_type": "response",
        "sbj_tok_span": [7, 11],
        "obj_tok_span": [21, 25]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "We found that treatment with ponatinib and vorinostat significantly inhibited T315I mutant cell growth compared to treatment with single drugs ( ) .",
    "entity_list": [
      {
        "name": "ponatinib",
        "ent_type": "drug",
        "char_span": [29, 38],
        "tok_span": [5, 9]
      },
      {
        "name": "T315I",
        "ent_type": "variant",
        "char_span": [78, 83],
        "tok_span": [16, 20]
      }
    ],
    "relation_list": [
      {
        "subject": "T315I",
        "object": "ponatinib",
        "sbj_char_span": [78, 83],
        "obj_char_span": [29, 38],
        "rel_type": "response",
        "sbj_tok_span": [16, 20],
        "obj_tok_span": [5, 9]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Effects of ponatinib and HDACi on T315I mutant cells in a xenograft model",
    "entity_list": [
      {
        "name": "ponatinib",
        "ent_type": "drug",
        "char_span": [11, 20],
        "tok_span": [2, 6]
      },
      {
        "name": "T315I",
        "ent_type": "variant",
        "char_span": [34, 39],
        "tok_span": [10, 14]
      }
    ],
    "relation_list": [
      {
        "subject": "T315I",
        "object": "ponatinib",
        "sbj_char_span": [34, 39],
        "obj_char_span": [11, 20],
        "rel_type": "response",
        "sbj_tok_span": [10, 14],
        "obj_tok_span": [2, 6]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "These results indicated that co-treatment with ponatinib and vorinostat was effective against T315I mutant cells in the xenograft model ( ) .",
    "entity_list": [
      {
        "name": "ponatinib",
        "ent_type": "drug",
        "char_span": [47, 56],
        "tok_span": [8, 12]
      },
      {
        "name": "T315I",
        "ent_type": "variant",
        "char_span": [94, 99],
        "tok_span": [20, 24]
      }
    ],
    "relation_list": [
      {
        "subject": "T315I",
        "object": "ponatinib",
        "sbj_char_span": [94, 99],
        "obj_char_span": [47, 56],
        "rel_type": "response",
        "sbj_tok_span": [20, 24],
        "obj_tok_span": [8, 12]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "10.1371/journal.pone.0089080.g003Effects of ponatinib and vorinostat on Ba/F3 T315I cells in a xenograft model .",
    "entity_list": [
      {
        "name": "ponatinib",
        "ent_type": "drug",
        "char_span": [44, 53],
        "tok_span": [21, 25]
      },
      {
        "name": "T315I",
        "ent_type": "variant",
        "char_span": [78, 83],
        "tok_span": [35, 39]
      }
    ],
    "relation_list": [
      {
        "subject": "T315I",
        "object": "ponatinib",
        "sbj_char_span": [78, 83],
        "obj_char_span": [44, 53],
        "rel_type": "response",
        "sbj_tok_span": [35, 39],
        "obj_tok_span": [21, 25]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Ponatinib is effective against T315I mutant cells that are resistant to imatinib and second-generation ABL TKIs nilotinib and dasatinib .",
    "entity_list": [
      {
        "name": "Ponatinib",
        "ent_type": "drug",
        "char_span": [0, 9],
        "tok_span": [0, 2]
      },
      {
        "name": "T315I",
        "ent_type": "variant",
        "char_span": [31, 36],
        "tok_span": [5, 9]
      }
    ],
    "relation_list": [
      {
        "subject": "T315I",
        "object": "Ponatinib",
        "sbj_char_span": [31, 36],
        "obj_char_span": [0, 9],
        "rel_type": "response",
        "sbj_tok_span": [5, 9],
        "obj_tok_span": [0, 2]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Using the Ba/F3 T315I xenograft model , ponatinib or vorinostat ( 30 and 70 mg/kg , respectively ) showed similar reduction in tumor size .",
    "entity_list": [
      {
        "name": "ponatinib",
        "ent_type": "drug",
        "char_span": [40, 49],
        "tok_span": [14, 18]
      },
      {
        "name": "T315I",
        "ent_type": "variant",
        "char_span": [16, 21],
        "tok_span": [6, 10]
      }
    ],
    "relation_list": [
      {
        "subject": "T315I",
        "object": "ponatinib",
        "sbj_char_span": [16, 21],
        "obj_char_span": [40, 49],
        "rel_type": "response",
        "sbj_tok_span": [6, 10],
        "obj_tok_span": [14, 18]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "In a recently concluded phase I clinical trial , the multikinase and pan-BCR-ABL1 inhibitor , ponatinib ( AP24534 ) induced a complete cytogenetic and major molecular response rates of 89 % and 78 % , respectively , in CML patients with T315I , and most responses were maintained after 12 months of follow-up .",
    "entity_list": [
      {
        "name": "ponatinib",
        "ent_type": "drug",
        "char_span": [94, 103],
        "tok_span": [22, 26]
      },
      {
        "name": "T315I",
        "ent_type": "variant",
        "char_span": [237, 242],
        "tok_span": [55, 59]
      },
      {
        "name": "AP24534",
        "ent_type": "drug",
        "char_span": [106, 113],
        "tok_span": [27, 31]
      }
    ],
    "relation_list": [
      {
        "subject": "T315I",
        "object": "ponatinib",
        "sbj_char_span": [237, 242],
        "obj_char_span": [94, 103],
        "rel_type": "response",
        "sbj_tok_span": [55, 59],
        "obj_tok_span": [22, 26]
      },
      {
        "subject": "T315I",
        "object": "AP24534",
        "sbj_char_span": [237, 242],
        "obj_char_span": [106, 113],
        "rel_type": "response",
        "sbj_tok_span": [55, 59],
        "obj_tok_span": [27, 31]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "It was reported that the L858R mutation enhances gefitinib sensitivity due to a structural change in the kinase domain resulting in an increased binding affinity of gefitinib for its ATP binding pocket in vitro .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [49, 58],
        "tok_span": [11, 15]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [25, 30],
        "tok_span": [5, 9]
      },
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [165, 174],
        "tok_span": [32, 36]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "gefitinib",
        "sbj_char_span": [25, 30],
        "obj_char_span": [49, 58],
        "rel_type": "sensitivity",
        "sbj_tok_span": [5, 9],
        "obj_tok_span": [11, 15]
      },
      {
        "subject": "L858R",
        "object": "gefitinib",
        "sbj_char_span": [25, 30],
        "obj_char_span": [165, 174],
        "rel_type": "sensitivity",
        "sbj_tok_span": [5, 9],
        "obj_tok_span": [32, 36]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "To obtain a logical understanding of the gefitinib sensitivity associated with L858R mutation , the mathematical analysis of the EGFR signaling pathway should be more preferable rather than sole experimental representations .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [41, 50],
        "tok_span": [7, 11]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [79, 84],
        "tok_span": [14, 18]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "gefitinib",
        "sbj_char_span": [79, 84],
        "obj_char_span": [41, 50],
        "rel_type": "sensitivity",
        "sbj_tok_span": [14, 18],
        "obj_tok_span": [7, 11]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Also , we found that EGFR-WT model at lower concentrations of EGF is as sensitive to gefitinib for ERK phosphorylation as L858R model A ( data not shown ) .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [85, 94],
        "tok_span": [18, 22]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [122, 127],
        "tok_span": [26, 30]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "gefitinib",
        "sbj_char_span": [122, 127],
        "obj_char_span": [85, 94],
        "rel_type": "sensitivity",
        "sbj_tok_span": [26, 30],
        "obj_tok_span": [18, 22]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "The multiplying coefficient α is given by α = ( k3 ) / ( k3 in EGFR-WT model or L858R models ) . α = 1 means without gefitinib .",
    "entity_list": [
      {
        "name": "without gefitinib",
        "ent_type": "drug",
        "char_span": [109, 126],
        "tok_span": [34, 39]
      },
      {
        "name": "or L858R",
        "ent_type": "variant",
        "char_span": [77, 85],
        "tok_span": [22, 27]
      }
    ],
    "relation_list": [
      {
        "subject": "or L858R",
        "object": "without gefitinib",
        "sbj_char_span": [77, 85],
        "obj_char_span": [109, 126],
        "rel_type": "sensitivity",
        "sbj_tok_span": [22, 27],
        "obj_tok_span": [34, 39]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "The combination of Mig6 and gefitinib has a synergistic effect in inhibiting EGFR signaling The only difference between the EGFR-WT model and the L858R model A is in the negative EGFR regulation produced by Mig6 , therefore , which can be experimentally verified by overexpressing Mig6 .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [28, 37],
        "tok_span": [7, 11]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [146, 151],
        "tok_span": [30, 34]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "gefitinib",
        "sbj_char_span": [146, 151],
        "obj_char_span": [28, 37],
        "rel_type": "sensitivity",
        "sbj_tok_span": [30, 34],
        "obj_tok_span": [7, 11]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "There were also no significant differences in survival time after the gefitinib treatment between the patients with exon 19 deletions and L858R ( Kaplan–Meier , logrank : P & lt ; 0.455 ) .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [70, 79],
        "tok_span": [11, 15]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [138, 143],
        "tok_span": [24, 28]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "gefitinib",
        "sbj_char_span": [138, 143],
        "obj_char_span": [70, 79],
        "rel_type": "sensitivity",
        "sbj_tok_span": [24, 28],
        "obj_tok_span": [11, 15]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "More recently , Chang et al. confirmed that in the absence of the common second-site EGFR mutation T790M or MET amplification , acquired resistance to gefitinib occurs in EGFR mutated PC9 cells that have undergone EMT .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [151, 160],
        "tok_span": [31, 35]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [99, 104],
        "tok_span": [20, 24]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "gefitinib",
        "sbj_char_span": [99, 104],
        "obj_char_span": [151, 160],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [20, 24],
        "obj_tok_span": [31, 35]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "NSCLC tumors carrying EGFR activating mutations ( e.g. , exon 19 deletions or L858R ) respond preferentially to the EGFR TKIs gefitinib and erlotinib .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [126, 135],
        "tok_span": [28, 32]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [78, 83],
        "tok_span": [16, 20]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "gefitinib",
        "sbj_char_span": [78, 83],
        "obj_char_span": [126, 135],
        "rel_type": "sensitivity",
        "sbj_tok_span": [16, 20],
        "obj_tok_span": [28, 32]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "However , in patients with acquired resistance , tumor cells bearing EGFR T790M represented a minority of cells , and as such , part of the tumor may remain responsive to erlotinib or gefitinib. , The other signal pathway related EGFR followed the same principles .",
    "entity_list": [
      {
        "name": "gefitinib.",
        "ent_type": "drug",
        "char_span": [184, 194],
        "tok_span": [39, 44]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [74, 79],
        "tok_span": [12, 16]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "gefitinib.",
        "sbj_char_span": [74, 79],
        "obj_char_span": [184, 194],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [12, 16],
        "obj_tok_span": [39, 44]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "In addition to the EGFR overexpressed cells , we also showed the phosphorylation status of EGFR-Thr654 and -Ser1046 in endogenous L858R mutant cells ( H1975 ) under treatment of VE-465 and Iressa ( ) .",
    "entity_list": [
      {
        "name": "Iressa",
        "ent_type": "drug",
        "char_span": [189, 195],
        "tok_span": [46, 49]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [130, 135],
        "tok_span": [27, 31]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "Iressa",
        "sbj_char_span": [130, 135],
        "obj_char_span": [189, 195],
        "rel_type": "sensitivity",
        "sbj_tok_span": [27, 31],
        "obj_tok_span": [46, 49]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "However , EGFR mutations was not a significant prognostic factor in an initial two large retrospective studies in surgically treated patients without gefitinib treatment ( ; ) , although reported that patients with exon 19 deletion have significantly shorter survival than those with L858R , but this is not confirmed by other investigators so far .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [150, 159],
        "tok_span": [22, 26]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [284, 289],
        "tok_span": [46, 50]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "gefitinib",
        "sbj_char_span": [284, 289],
        "obj_char_span": [150, 159],
        "rel_type": "sensitivity",
        "sbj_tok_span": [46, 50],
        "obj_tok_span": [22, 26]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "However , an in vitro study showed that the growth of NSCLC cell lines harboring exon 19 deletion or L858R mutation were almost equally inhibited by equivalent concentrations of gefitinib , and the degree of EGFR phosphorylation . ",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [178, 187],
        "tok_span": [32, 36]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [101, 106],
        "tok_span": [19, 23]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "gefitinib",
        "sbj_char_span": [101, 106],
        "obj_char_span": [178, 187],
        "rel_type": "sensitivity",
        "sbj_tok_span": [19, 23],
        "obj_tok_span": [32, 36]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Besides , previous studies revealed that patients with exon 18 ( G719S ) plus L858R mutation showed poor outcomes with gefitinib , , .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [119, 128],
        "tok_span": [26, 30]
      },
      {
        "name": "G719S",
        "ent_type": "variant",
        "char_span": [65, 70],
        "tok_span": [11, 15]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [78, 83],
        "tok_span": [17, 21]
      }
    ],
    "relation_list": [
      {
        "subject": "G719S",
        "object": "gefitinib",
        "sbj_char_span": [65, 70],
        "obj_char_span": [119, 128],
        "rel_type": "sensitivity",
        "sbj_tok_span": [11, 15],
        "obj_tok_span": [26, 30]
      },
      {
        "subject": "L858R",
        "object": "gefitinib",
        "sbj_char_span": [78, 83],
        "obj_char_span": [119, 128],
        "rel_type": "sensitivity",
        "sbj_tok_span": [17, 21],
        "obj_tok_span": [26, 30]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Another seven studies ( clinical trials or retrospective studies ) , , , , , , involving 549 advanced NSCLC patients receiving first-line EGFR-TKIs ( gefitinib or erlotinib ) presented direct comparison of exon 19 deletion and L858R mutation for PFS .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [150, 159],
        "tok_span": [31, 35]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [227, 232],
        "tok_span": [49, 53]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "gefitinib",
        "sbj_char_span": [227, 232],
        "obj_char_span": [150, 159],
        "rel_type": "sensitivity",
        "sbj_tok_span": [49, 53],
        "obj_tok_span": [31, 35]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "The L858R mutant was 10–100 fold more sensitive to erlotinib and gefitinib than the wild type kinase , .",
    "entity_list": [
      {
        "name": "and gefitinib",
        "ent_type": "drug",
        "char_span": [61, 74],
        "tok_span": [18, 23]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [4, 9],
        "tok_span": [1, 5]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "and gefitinib",
        "sbj_char_span": [4, 9],
        "obj_char_span": [61, 74],
        "rel_type": "sensitivity",
        "sbj_tok_span": [1, 5],
        "obj_tok_span": [18, 23]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Non-small cell lung cancer patients with L858R or exon 19 deletion mutations in EGFR show good responses to the tyrosine kinase inhibitor gefitinib .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [138, 147],
        "tok_span": [27, 31]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [41, 46],
        "tok_span": [8, 12]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "gefitinib",
        "sbj_char_span": [41, 46],
        "obj_char_span": [138, 147],
        "rel_type": "sensitivity",
        "sbj_tok_span": [8, 12],
        "obj_tok_span": [27, 31]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Likewise , the T790M mutation in the EGFR gene rose after chronic exposure to Gefitinib in NSCLC , conferring resistance to this inhibitor .",
    "entity_list": [
      {
        "name": "Gefitinib",
        "ent_type": "drug",
        "char_span": [78, 87],
        "tok_span": [17, 20]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [15, 20],
        "tok_span": [3, 7]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "Gefitinib",
        "sbj_char_span": [15, 20],
        "obj_char_span": [78, 87],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [3, 7],
        "obj_tok_span": [17, 20]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Furthermore , the biopsy of the breast metastasis revealed the second mutation of resistance to gefitinib in the epidermal growth factor receptor (EGFR) gene ( T790M ) .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [96, 105],
        "tok_span": [15, 19]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [160, 165],
        "tok_span": [30, 34]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "gefitinib",
        "sbj_char_span": [160, 165],
        "obj_char_span": [96, 105],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [30, 34],
        "obj_tok_span": [15, 19]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "For example , patients with epidermal growth factor receptor (EGFR) mutations , most frequently exon 19 deletions and exon 21 point mutation L858R may respond to EGFR–TKI , like gefitinib or erlotinib .",
    "entity_list": [
      {
        "name": "like gefitinib",
        "ent_type": "drug",
        "char_span": [173, 187],
        "tok_span": [36, 41]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [141, 146],
        "tok_span": [24, 28]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "like gefitinib",
        "sbj_char_span": [141, 146],
        "obj_char_span": [173, 187],
        "rel_type": "sensitivity",
        "sbj_tok_span": [24, 28],
        "obj_tok_span": [36, 41]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Resistance of a NSCLC Cell Line Harboring Both T790M and L858R Mutations to Gefitinib or Erlotinib",
    "entity_list": [
      {
        "name": "Erlotinib",
        "ent_type": "drug",
        "char_span": [89, 98],
        "tok_span": [25, 28]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [57, 62],
        "tok_span": [15, 19]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [47, 52],
        "tok_span": [10, 14]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "Erlotinib",
        "sbj_char_span": [57, 62],
        "obj_char_span": [89, 98],
        "rel_type": "sensitivity",
        "sbj_tok_span": [15, 19],
        "obj_tok_span": [25, 28]
      },
      {
        "subject": "T790M",
        "object": "Erlotinib",
        "sbj_char_span": [47, 52],
        "obj_char_span": [89, 98],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [10, 14],
        "obj_tok_span": [25, 28]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "How tumor cells bearing the T790M mutation emerge within gefitinib- or erlotinib treated patients is a matter of investigation .",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [71, 80],
        "tok_span": [18, 22]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [28, 33],
        "tok_span": [5, 9]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "erlotinib",
        "sbj_char_span": [28, 33],
        "obj_char_span": [71, 80],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [5, 9],
        "obj_tok_span": [18, 22]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "In either scenario , treatment with gefitinib or erlotinib subsequently allows these resistant subclones to become apparent , because most cells bearing sensitivity conferring mutations die , while cells with the T790M mutation persist .",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [49, 58],
        "tok_span": [11, 15]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [213, 218],
        "tok_span": [39, 43]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "erlotinib",
        "sbj_char_span": [213, 218],
        "obj_char_span": [49, 58],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [39, 43],
        "obj_tok_span": [11, 15]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "We found that the mechanism of erlotinib resistance of HCC827TR3 was neither c-Met amplification nor T790M mutation in EGFR ( data not shown ) .",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [31, 40],
        "tok_span": [6, 10]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [101, 106],
        "tok_span": [24, 28]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "erlotinib",
        "sbj_char_span": [101, 106],
        "obj_char_span": [31, 40],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [24, 28],
        "obj_tok_span": [6, 10]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "It has been shown that exon 19 deletions are more sensitive to erlotinib inhibition than the L858R mutation , a finding demonstrated by kinetic analysis and also confirmed in clinical studies .",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [63, 72],
        "tok_span": [12, 16]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [93, 98],
        "tok_span": [19, 23]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "erlotinib",
        "sbj_char_span": [93, 98],
        "obj_char_span": [63, 72],
        "rel_type": "sensitivity",
        "sbj_tok_span": [19, 23],
        "obj_tok_span": [12, 16]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "The most commonly identified mechanism of resistance is an EGFR mutation at position 790 ( T790M ) , resulting in substitution of a threonine residue with methionine , which abrogates the ability of gefitinib or erlotinib to inhibit EGFR .",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [212, 221],
        "tok_span": [45, 49]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [91, 96],
        "tok_span": [16, 20]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "erlotinib",
        "sbj_char_span": [91, 96],
        "obj_char_span": [212, 221],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [16, 20],
        "obj_tok_span": [45, 49]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "The bulkier methionine residue T790M changes the ATP binding pocket of the tyrosine kinase domain , leading to the blockade of gefitinib or erlotinib .",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [140, 149],
        "tok_span": [30, 34]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [31, 36],
        "tok_span": [5, 9]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "erlotinib",
        "sbj_char_span": [31, 36],
        "obj_char_span": [140, 149],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [5, 9],
        "obj_tok_span": [30, 34]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "However , it was demonstrated recently that T790M increased the affinity of ATP to the EGFR tyrosine kinase domain ; thus , it decreased the binding of gefitinib and erlotinib , because they are ATP-competitive agents .",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [166, 175],
        "tok_span": [35, 39]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [44, 49],
        "tok_span": [7, 11]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "erlotinib",
        "sbj_char_span": [44, 49],
        "obj_char_span": [166, 175],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [7, 11],
        "obj_tok_span": [35, 39]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "In the xenograft model of mice , the combination of cetuximab and afatinib can lead to a significant reduction of erlotinib-resistant tumor harboring T790M , compared to gefitinib plus cetuximab .",
    "entity_list": [
      {
        "name": "erlotinib-resistant",
        "ent_type": "drug",
        "char_span": [114, 133],
        "tok_span": [25, 31]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [150, 155],
        "tok_span": [33, 37]
      },
      {
        "name": "cetuximab",
        "ent_type": "drug",
        "char_span": [52, 61],
        "tok_span": [11, 15]
      },
      {
        "name": "cetuximab",
        "ent_type": "drug",
        "char_span": [185, 194],
        "tok_span": [45, 49]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "erlotinib-resistant",
        "sbj_char_span": [150, 155],
        "obj_char_span": [114, 133],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [33, 37],
        "obj_tok_span": [25, 31]
      },
      {
        "subject": "T790M",
        "object": "cetuximab",
        "sbj_char_span": [150, 155],
        "obj_char_span": [52, 61],
        "rel_type": "response",
        "sbj_tok_span": [33, 37],
        "obj_tok_span": [11, 15]
      },
      {
        "subject": "T790M",
        "object": "cetuximab",
        "sbj_char_span": [150, 155],
        "obj_char_span": [185, 194],
        "rel_type": "response",
        "sbj_tok_span": [33, 37],
        "obj_tok_span": [45, 49]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "These preclinical models suggest that dacomitinib may be quite effective against lung cancer that becomes resistant to gefitinib or erlotinib via acquisition of a T790M mutation in EGFR .",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [132, 141],
        "tok_span": [25, 29]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [163, 168],
        "tok_span": [33, 37]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "erlotinib",
        "sbj_char_span": [163, 168],
        "obj_char_span": [132, 141],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [33, 37],
        "obj_tok_span": [25, 29]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Furthermore , the NSCLC cell line H1975 harbors both the L858R and T790M mutations , and is resistant to inhibition by gefitinib or erlotinib , unlike cell lines that express the L858R allele alone .",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [132, 141],
        "tok_span": [35, 39]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [57, 62],
        "tok_span": [13, 17]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [67, 72],
        "tok_span": [18, 22]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "erlotinib",
        "sbj_char_span": [57, 62],
        "obj_char_span": [132, 141],
        "rel_type": "sensitivity",
        "sbj_tok_span": [13, 17],
        "obj_tok_span": [35, 39]
      },
      {
        "subject": "T790M",
        "object": "erlotinib",
        "sbj_char_span": [67, 72],
        "obj_char_span": [132, 141],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [18, 22],
        "obj_tok_span": [35, 39]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "For tyrosine kinase inhibitors ( TKIs ) , mutations within the ATP pocket of the kinase domain may affect the interaction of the drug with its target : for example , the single amino acid mutation tyrosine/methionine ( T790M ) in the ATP binding pocket of the EGFR mediates secondary resistance to the EGFR TKIs erlotinib and gefitinib in non-small cell lung cancer ( NSCLC ) .",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [312, 321],
        "tok_span": [62, 66]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [219, 224],
        "tok_span": [41, 45]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "erlotinib",
        "sbj_char_span": [219, 224],
        "obj_char_span": [312, 321],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [41, 45],
        "obj_tok_span": [62, 66]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Further studies of gefitinib revealed that this 4-anilinoquinazoline inhibitor , structurally similar to erlotinib , binds the EGFR c.2573T & gt ; G ( L858R ) mutant with a 20-fold higher affinity compared to the wild-type enzyme . ",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [105, 114],
        "tok_span": [22, 26]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [151, 156],
        "tok_span": [41, 45]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "erlotinib",
        "sbj_char_span": [151, 156],
        "obj_char_span": [105, 114],
        "rel_type": "sensitivity",
        "sbj_tok_span": [41, 45],
        "obj_tok_span": [22, 26]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Di Nicolantonio et al also demonstrated that introduction of the B-RAF V600E allele could confer resistance to either cetuximab or panitumumab in wild-type B-RAF colorectal cancer cells .",
    "entity_list": [
      {
        "name": "cetuximab",
        "ent_type": "drug",
        "char_span": [118, 127],
        "tok_span": [27, 31]
      },
      {
        "name": "V600E",
        "ent_type": "variant",
        "char_span": [71, 76],
        "tok_span": [18, 21]
      },
      {
        "name": "panitumumab",
        "ent_type": "drug",
        "char_span": [131, 142],
        "tok_span": [32, 35]
      }
    ],
    "relation_list": [
      {
        "subject": "V600E",
        "object": "cetuximab",
        "sbj_char_span": [71, 76],
        "obj_char_span": [118, 127],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [18, 21],
        "obj_tok_span": [27, 31]
      },
      {
        "subject": "V600E",
        "object": "panitumumab",
        "sbj_char_span": [71, 76],
        "obj_char_span": [131, 142],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [18, 21],
        "obj_tok_span": [32, 35]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "In addition , the EGFR ectodomain mutation S492R has recently been found to confer resistance to cetuximab .",
    "entity_list": [
      {
        "name": "cetuximab",
        "ent_type": "drug",
        "char_span": [97, 106],
        "tok_span": [21, 25]
      },
      {
        "name": "S492R",
        "ent_type": "variant",
        "char_span": [43, 48],
        "tok_span": [9, 13]
      }
    ],
    "relation_list": [
      {
        "subject": "S492R",
        "object": "cetuximab",
        "sbj_char_span": [43, 48],
        "obj_char_span": [97, 106],
        "rel_type": "resistance",
        "sbj_tok_span": [9, 13],
        "obj_tok_span": [21, 25]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Consistent with this hypothesis , in a recent meta-analysis of cetuximab clinical trial data , clearly demonstrated that patients with colorectal tumours with a G13D mutation were significantly more likely to respond to cetuximab treatment than other K-Ras mutant tumours and survived longer .",
    "entity_list": [
      {
        "name": "cetuximab",
        "ent_type": "drug",
        "char_span": [63, 72],
        "tok_span": [12, 16]
      },
      {
        "name": "G13D",
        "ent_type": "variant",
        "char_span": [161, 165],
        "tok_span": [29, 32]
      },
      {
        "name": "cetuximab",
        "ent_type": "drug",
        "char_span": [220, 229],
        "tok_span": [40, 44]
      }
    ],
    "relation_list": [
      {
        "subject": "G13D",
        "object": "cetuximab",
        "sbj_char_span": [161, 165],
        "obj_char_span": [63, 72],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [29, 32],
        "obj_tok_span": [12, 16]
      },
      {
        "subject": "G13D",
        "object": "cetuximab",
        "sbj_char_span": [161, 165],
        "obj_char_span": [220, 229],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [29, 32],
        "obj_tok_span": [40, 44]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "However , Stover et al reported that nilotinib could not overcome the imatinib resistance conferred by the point mutation T674I in FIP1L1-PDGFRA in the same cellular model , even at high concentrations .",
    "entity_list": [
      {
        "name": "imatinib",
        "ent_type": "drug",
        "char_span": [70, 78],
        "tok_span": [15, 17]
      },
      {
        "name": "T674I",
        "ent_type": "variant",
        "char_span": [122, 127],
        "tok_span": [24, 28]
      }
    ],
    "relation_list": [
      {
        "subject": "T674I",
        "object": "imatinib",
        "sbj_char_span": [122, 127],
        "obj_char_span": [70, 78],
        "rel_type": "resistance",
        "sbj_tok_span": [24, 28],
        "obj_tok_span": [15, 17]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Other examples of useful biomarkers are KRAS mutation testing to predict benefit from monoclonal antibodies against EGFR , cetuximab and panitumumab , in metastatic colon cancer and BRAF V600E mutation analysis in metastatic melanoma in order to predict responsiveness to BRAF inhibitors such as vemurafenib .",
    "entity_list": [
      {
        "name": "panitumumab",
        "ent_type": "drug",
        "char_span": [137, 148],
        "tok_span": [24, 27]
      },
      {
        "name": "V600E",
        "ent_type": "variant",
        "char_span": [187, 192],
        "tok_span": [34, 37]
      }
    ],
    "relation_list": [
      {
        "subject": "V600E",
        "object": "panitumumab",
        "sbj_char_span": [187, 192],
        "obj_char_span": [137, 148],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [34, 37],
        "obj_tok_span": [24, 27]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "However , the ability of crizotinib to inhibit ALK phosphorylation was substantially reduced in all mutants tested , with IC50s & gt ; 1000 nm for L1196M and G1269S ( ) .",
    "entity_list": [
      {
        "name": "crizotinib",
        "ent_type": "drug",
        "char_span": [25, 35],
        "tok_span": [5, 9]
      },
      {
        "name": "L1196M",
        "ent_type": "variant",
        "char_span": [147, 153],
        "tok_span": [33, 37]
      }
    ],
    "relation_list": [
      {
        "subject": "L1196M",
        "object": "crizotinib",
        "sbj_char_span": [147, 153],
        "obj_char_span": [25, 35],
        "rel_type": "resistance",
        "sbj_tok_span": [33, 37],
        "obj_tok_span": [5, 9]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Impact of L1196M on anti-ALK activity of crizotinib and TAE684 .",
    "entity_list": [
      {
        "name": "crizotinib",
        "ent_type": "drug",
        "char_span": [41, 51],
        "tok_span": [13, 17]
      },
      {
        "name": "L1196M",
        "ent_type": "variant",
        "char_span": [10, 16],
        "tok_span": [2, 6]
      }
    ],
    "relation_list": [
      {
        "subject": "L1196M",
        "object": "crizotinib",
        "sbj_char_span": [10, 16],
        "obj_char_span": [41, 51],
        "rel_type": "resistance",
        "sbj_tok_span": [2, 6],
        "obj_tok_span": [13, 17]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "L1196M and L1152R mutations confer resistance to crizotinib via steric interference .",
    "entity_list": [
      {
        "name": "crizotinib",
        "ent_type": "drug",
        "char_span": [49, 59],
        "tok_span": [13, 17]
      },
      {
        "name": "L1196M",
        "ent_type": "variant",
        "char_span": [0, 6],
        "tok_span": [0, 4]
      },
      {
        "name": "L1152R",
        "ent_type": "variant",
        "char_span": [11, 17],
        "tok_span": [5, 9]
      }
    ],
    "relation_list": [
      {
        "subject": "L1196M",
        "object": "crizotinib",
        "sbj_char_span": [0, 6],
        "obj_char_span": [49, 59],
        "rel_type": "resistance",
        "sbj_tok_span": [0, 4],
        "obj_tok_span": [13, 17]
      },
      {
        "subject": "L1152R",
        "object": "crizotinib",
        "sbj_char_span": [11, 17],
        "obj_char_span": [49, 59],
        "rel_type": "resistance",
        "sbj_tok_span": [5, 9],
        "obj_tok_span": [13, 17]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "The strategies described here could also benefit patients with ALK translocated cancers , where the F1174L mutation modulates crizotinib resistance and the same signaling pathways that drive tumor cells without translocated ALK are active .",
    "entity_list": [
      {
        "name": "crizotinib",
        "ent_type": "drug",
        "char_span": [126, 136],
        "tok_span": [23, 27]
      },
      {
        "name": "F1174L",
        "ent_type": "variant",
        "char_span": [100, 106],
        "tok_span": [17, 21]
      }
    ],
    "relation_list": [
      {
        "subject": "F1174L",
        "object": "crizotinib",
        "sbj_char_span": [100, 106],
        "obj_char_span": [126, 136],
        "rel_type": "resistance",
        "sbj_tok_span": [17, 21],
        "obj_tok_span": [23, 27]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Another mutation , F1174L , has been identified in a patient with inflammatory myofibroblastic tumor and RANPB2-ALK translocation who relapsed on crizotinib therapy ( Ou , 2011 ) .",
    "entity_list": [
      {
        "name": "crizotinib",
        "ent_type": "drug",
        "char_span": [146, 156],
        "tok_span": [33, 37]
      },
      {
        "name": "F1174L",
        "ent_type": "variant",
        "char_span": [19, 25],
        "tok_span": [3, 7]
      }
    ],
    "relation_list": [
      {
        "subject": "F1174L",
        "object": "crizotinib",
        "sbj_char_span": [19, 25],
        "obj_char_span": [146, 156],
        "rel_type": "resistance",
        "sbj_tok_span": [3, 7],
        "obj_tok_span": [33, 37]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Inhibition of EGFR cell lines by afatinib compared to erlotinib as shown by EC50 values Wild-type L858R mutation L858R + T790M",
    "entity_list": [
      {
        "name": "afatinib",
        "ent_type": "drug",
        "char_span": [33, 41],
        "tok_span": [6, 8]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [98, 103],
        "tok_span": [23, 27]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [121, 126],
        "tok_span": [33, 37]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "afatinib",
        "sbj_char_span": [98, 103],
        "obj_char_span": [33, 41],
        "rel_type": "sensitivity",
        "sbj_tok_span": [23, 27],
        "obj_tok_span": [6, 8]
      },
      {
        "subject": "T790M",
        "object": "afatinib",
        "sbj_char_span": [121, 126],
        "obj_char_span": [33, 41],
        "rel_type": "response",
        "sbj_tok_span": [33, 37],
        "obj_tok_span": [6, 8]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Strategies to improve EGFR inhibition in EGFR T790M cancers include the combination of irreversible EGFR inhibitors with the EGFR‐directed antibody cetuximab ( as reported for afatinib plus cetuximab ) 19 ; the development of more potent and specific inhibitors of EGFR T790M20,21 ; and the use of intermittent but high doses of existing irreversible EGFR inhibitors .",
    "entity_list": [
      {
        "name": "for afatinib",
        "ent_type": "drug",
        "char_span": [172, 184],
        "tok_span": [32, 35]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [46, 51],
        "tok_span": [7, 11]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "for afatinib",
        "sbj_char_span": [46, 51],
        "obj_char_span": [172, 184],
        "rel_type": "response",
        "sbj_tok_span": [7, 11],
        "obj_tok_span": [32, 35]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "By contrast , ponatinib induced loss of cell viability in BaF3 cells carrying the T315I or G250E mutation , in agreement with previous results from the literature .",
    "entity_list": [
      {
        "name": "ponatinib",
        "ent_type": "drug",
        "char_span": [14, 23],
        "tok_span": [3, 7]
      },
      {
        "name": "T315I",
        "ent_type": "variant",
        "char_span": [82, 87],
        "tok_span": [19, 23]
      }
    ],
    "relation_list": [
      {
        "subject": "T315I",
        "object": "ponatinib",
        "sbj_char_span": [82, 87],
        "obj_char_span": [14, 23],
        "rel_type": "response",
        "sbj_tok_span": [19, 23],
        "obj_tok_span": [3, 7]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "The availability of 3D-structure of the target protein and the structural details of ponatinib and T315I mutant BCR-ABL protein complex renders an opportunity to identify the most active drug candidate that can efficiently block the catalytic activity of BCR-ABL .",
    "entity_list": [
      {
        "name": "ponatinib",
        "ent_type": "drug",
        "char_span": [85, 94],
        "tok_span": [16, 20]
      },
      {
        "name": "T315I",
        "ent_type": "variant",
        "char_span": [99, 104],
        "tok_span": [21, 25]
      }
    ],
    "relation_list": [
      {
        "subject": "T315I",
        "object": "ponatinib",
        "sbj_char_span": [99, 104],
        "obj_char_span": [85, 94],
        "rel_type": "response",
        "sbj_tok_span": [21, 25],
        "obj_tok_span": [16, 20]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "A specific mutation ( del746–750 ) is found to be superior to other ( L858R ) mutations for the prediction of response to gefitinib .",
    "entity_list": [
      {
        "name": "to gefitinib",
        "ent_type": "drug",
        "char_span": [119, 131],
        "tok_span": [29, 34]
      },
      {
        "name": "( L858R",
        "ent_type": "variant",
        "char_span": [68, 75],
        "tok_span": [17, 22]
      }
    ],
    "relation_list": [
      {
        "subject": "( L858R",
        "object": "to gefitinib",
        "sbj_char_span": [68, 75],
        "obj_char_span": [119, 131],
        "rel_type": "sensitivity",
        "sbj_tok_span": [17, 22],
        "obj_tok_span": [29, 34]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "The exon 20 T790M mutation previously documented to confer resistance to gefitinib was not observed .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [73, 82],
        "tok_span": [14, 18]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [12, 17],
        "tok_span": [3, 7]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "gefitinib",
        "sbj_char_span": [12, 17],
        "obj_char_span": [73, 82],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [3, 7],
        "obj_tok_span": [14, 18]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Afatinib was more potent than gefitinib , erlotinib , and lapatinib in inducing the cell death of NSCLC cell lines , including those harboring wild-type EGFR , and the erlotinib-resistant T790M mutation .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [30, 39],
        "tok_span": [6, 10]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [188, 193],
        "tok_span": [46, 50]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "gefitinib",
        "sbj_char_span": [188, 193],
        "obj_char_span": [30, 39],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [46, 50],
        "obj_tok_span": [6, 10]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Surprisingly , the EGFR L858R mutation leads to decreased ability to activate ERK compared to WT EGFR which correlates with decreased EGFR internalization , reduced phosphorylation of SHP2 , hyperactivity of STAT3 and reduced sensitivity to gefitinib .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [241, 250],
        "tok_span": [43, 47]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [24, 29],
        "tok_span": [4, 8]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "gefitinib",
        "sbj_char_span": [24, 29],
        "obj_char_span": [241, 250],
        "rel_type": "sensitivity",
        "sbj_tok_span": [4, 8],
        "obj_tok_span": [43, 47]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Although the sequence analysis of EGFR might be necessary for clinical trials using TKI such as gefitinib or erlotinib , these simple methods established in this study for detection of exon 19 deletion and exon 21 L858R mutation are very useful for screening .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [96, 105],
        "tok_span": [17, 21]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [214, 219],
        "tok_span": [43, 47]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "gefitinib",
        "sbj_char_span": [214, 219],
        "obj_char_span": [96, 105],
        "rel_type": "sensitivity",
        "sbj_tok_span": [43, 47],
        "obj_tok_span": [17, 21]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "The cell line H1975 has a sensitizing L858R kinase domain mutation in exon 21 , and a second T790M in exon 20 , in cis , in the EGFR kinase domain , rendering them resistant to the reversible TKIs gefitinib and erlotinib .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [197, 206],
        "tok_span": [49, 53]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [93, 98],
        "tok_span": [24, 28]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [38, 43],
        "tok_span": [10, 14]
      },
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [211, 220],
        "tok_span": [54, 58]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "gefitinib",
        "sbj_char_span": [93, 98],
        "obj_char_span": [197, 206],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [24, 28],
        "obj_tok_span": [49, 53]
      },
      {
        "subject": "L858R",
        "object": "gefitinib",
        "sbj_char_span": [38, 43],
        "obj_char_span": [197, 206],
        "rel_type": "sensitivity",
        "sbj_tok_span": [10, 14],
        "obj_tok_span": [49, 53]
      },
      {
        "subject": "L858R",
        "object": "erlotinib",
        "sbj_char_span": [38, 43],
        "obj_char_span": [211, 220],
        "rel_type": "sensitivity",
        "sbj_tok_span": [10, 14],
        "obj_tok_span": [54, 58]
      },
      {
        "subject": "T790M",
        "object": "erlotinib",
        "sbj_char_span": [93, 98],
        "obj_char_span": [211, 220],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [24, 28],
        "obj_tok_span": [54, 58]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Non-small cell lung cancer Kinase domain deletions ( exon 19 ) , point mutations ( exon 21 ) Gene amplification Erlotinib , Gefitinib T790M gatekeeper mutation ( 50 % ) , , elevated c-Met/HGF expression ( 20 % ) –",
    "entity_list": [
      {
        "name": "Gefitinib",
        "ent_type": "drug",
        "char_span": [124, 133],
        "tok_span": [27, 30]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [134, 139],
        "tok_span": [30, 34]
      },
      {
        "name": "Erlotinib",
        "ent_type": "drug",
        "char_span": [112, 121],
        "tok_span": [23, 26]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "Gefitinib",
        "sbj_char_span": [134, 139],
        "obj_char_span": [124, 133],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [30, 34],
        "obj_tok_span": [27, 30]
      },
      {
        "subject": "T790M",
        "object": "Erlotinib",
        "sbj_char_span": [134, 139],
        "obj_char_span": [112, 121],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [30, 34],
        "obj_tok_span": [23, 26]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "For example , detecting the T790M mutation in blood samples would be useful for patient selection for treatment with new EGFR-TKIs for lung cancers that are resistant to gefitinib and erlotinib .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [170, 179],
        "tok_span": [34, 38]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [28, 33],
        "tok_span": [5, 9]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "gefitinib",
        "sbj_char_span": [28, 33],
        "obj_char_span": [170, 179],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [5, 9],
        "obj_tok_span": [34, 38]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "L1196M represents a mutation of the “gatekeeper” residue , similar to the T790M gefitinib-resistance mutations observed in EGFR , and T315I mutations in ABL . ",
    "entity_list": [
      {
        "name": "T790M gefitinib-resistance",
        "ent_type": "variant",
        "char_span": [74, 100],
        "tok_span": [19, 29]
      },
      {
        "name": "the T790M",
        "ent_type": "variant",
        "char_span": [70, 79],
        "tok_span": [18, 23]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M gefitinib-resistance",
        "object": "the T790M",
        "sbj_char_span": [74, 100],
        "obj_char_span": [70, 79],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [19, 29],
        "obj_tok_span": [18, 23]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Many evidences showed that patients with advanced lung adenocarcinomas harbor EGFR mutations , L858R missense mutations at exon 21 or deletions in exon 19 were more sensitive to the EGFR-TKI erlotinib or gefitinib , , .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [204, 213],
        "tok_span": [43, 47]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [95, 100],
        "tok_span": [14, 18]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "gefitinib",
        "sbj_char_span": [95, 100],
        "obj_char_span": [204, 213],
        "rel_type": "sensitivity",
        "sbj_tok_span": [14, 18],
        "obj_tok_span": [43, 47]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Our data appear to support a previously unrecognized scenario in which , in the presence of erlotinib sensitizing EGFR mutations ( delE746-A750 , L858R ) , an aberrant/incomplete epithelial differentiation might determine the intrinsic ability of EGFR mutant-NSCLC cells to rapidly shift toward the erlotinib-refractory mesenchymal end of the epithelial-mesenchymal spectrum .",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [92, 101],
        "tok_span": [19, 23]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [146, 151],
        "tok_span": [37, 41]
      },
      {
        "name": "erlotinib-refractory",
        "ent_type": "drug",
        "char_span": [299, 319],
        "tok_span": [65, 71]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "erlotinib",
        "sbj_char_span": [146, 151],
        "obj_char_span": [92, 101],
        "rel_type": "sensitivity",
        "sbj_tok_span": [37, 41],
        "obj_tok_span": [19, 23]
      },
      {
        "subject": "L858R",
        "object": "erlotinib-refractory",
        "sbj_char_span": [146, 151],
        "obj_char_span": [299, 319],
        "rel_type": "sensitivity",
        "sbj_tok_span": [37, 41],
        "obj_tok_span": [65, 71]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Intense research efforts over the past few years have identified two major mechanisms of acquired resistance to gefitinib/erlotinib : secondary resistance mutations ( e.g. , T790M ) and “oncogene kinase switch” systems ( e.g. , MET amplification and AXL activation ) .",
    "entity_list": [
      {
        "name": "gefitinib/erlotinib",
        "ent_type": "drug",
        "char_span": [112, 131],
        "tok_span": [18, 27]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [174, 179],
        "tok_span": [37, 41]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "gefitinib/erlotinib",
        "sbj_char_span": [174, 179],
        "obj_char_span": [112, 131],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [37, 41],
        "obj_tok_span": [18, 27]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "The firstly described and the most common event responsible for resistance is the acquisition of the T790M missense mutation , which is found in ≈ 50 % of patients progressing after an initial response to erlotinib or gefitinib .",
    "entity_list": [
      {
        "name": "to erlotinib",
        "ent_type": "drug",
        "char_span": [202, 214],
        "tok_span": [39, 44]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [101, 106],
        "tok_span": [16, 20]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "to erlotinib",
        "sbj_char_span": [101, 106],
        "obj_char_span": [202, 214],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [16, 20],
        "obj_tok_span": [39, 44]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "The T790M “gatekeeper mutation” is associated with acquired resistance to Erlotinib in NSCLC ( see text for details and further references ) .",
    "entity_list": [
      {
        "name": "to Erlotinib",
        "ent_type": "drug",
        "char_span": [71, 83],
        "tok_span": [16, 20]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [4, 9],
        "tok_span": [1, 5]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "to Erlotinib",
        "sbj_char_span": [4, 9],
        "obj_char_span": [71, 83],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [1, 5],
        "obj_tok_span": [16, 20]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Intriguingly , erlotinib treated NSCLC that metastasized to the liver and the central nervous system ( CNS ) acquired the T790M mutation in the primary tumor and liver metastases , conferring drug resistance to these tumors , whereas the CNS tumors that did not acquire this mutation remained sensitive to erlotinib .",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [15, 24],
        "tok_span": [4, 8]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [122, 127],
        "tok_span": [27, 31]
      },
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [306, 315],
        "tok_span": [61, 65]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "erlotinib",
        "sbj_char_span": [122, 127],
        "obj_char_span": [15, 24],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [27, 31],
        "obj_tok_span": [4, 8]
      },
      {
        "subject": "T790M",
        "object": "erlotinib",
        "sbj_char_span": [122, 127],
        "obj_char_span": [306, 315],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [27, 31],
        "obj_tok_span": [61, 65]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "The detection of T790M was associated with the clinical responsiveness to erlotinib in this case .",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [74, 83],
        "tok_span": [14, 18]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [17, 22],
        "tok_span": [3, 7]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "erlotinib",
        "sbj_char_span": [17, 22],
        "obj_char_span": [74, 83],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [3, 7],
        "obj_tok_span": [14, 18]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Although these limitations exist , the different distribution of the cancer cells that had acquired the T790M mutation primarily explains the different response to erlotinib observed between the intracranial and extracranial sites in this case .",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [164, 173],
        "tok_span": [27, 31]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [104, 109],
        "tok_span": [16, 20]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "erlotinib",
        "sbj_char_span": [104, 109],
        "obj_char_span": [164, 173],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [16, 20],
        "obj_tok_span": [27, 31]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "For example , HCC827 cells undergo MET amplification and AXL induction upon adaption to gefitinib , , , and PC9 cells acquire the T790M mutation in EGFR that confers resistance to erlotinib and gefitinib . ",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [180, 189],
        "tok_span": [42, 46]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [130, 135],
        "tok_span": [31, 35]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "erlotinib",
        "sbj_char_span": [130, 135],
        "obj_char_span": [180, 189],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [31, 35],
        "obj_tok_span": [42, 46]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Similarly , the T790M point mutation in the epidermal growth factor receptor (EGFR) confers resistance to the EGFR tyrosine kinase inhibitors gefitinib and erlotinib , which are used to treat non-small cell lung cancer .",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [156, 165],
        "tok_span": [31, 35]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [16, 21],
        "tok_span": [3, 7]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "erlotinib",
        "sbj_char_span": [16, 21],
        "obj_char_span": [156, 165],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [3, 7],
        "obj_tok_span": [31, 35]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "H1975 cancer cell line with mutations in EGFR exons 21 ( L858R ) and 20 ( T790M ) was refractory to reversible EGFR-TKIs , gefitinib , and erlotinib , but was sensitive to irreversible EGFR-TKIs , such as BIBW2992 ( afatinib ) .",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [139, 148],
        "tok_span": [41, 45]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [57, 62],
        "tok_span": [13, 17]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [74, 79],
        "tok_span": [21, 25]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "erlotinib",
        "sbj_char_span": [57, 62],
        "obj_char_span": [139, 148],
        "rel_type": "sensitivity",
        "sbj_tok_span": [13, 17],
        "obj_tok_span": [41, 45]
      },
      {
        "subject": "T790M",
        "object": "erlotinib",
        "sbj_char_span": [74, 79],
        "obj_char_span": [139, 148],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [21, 25],
        "obj_tok_span": [41, 45]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Due to their ability to potently inhibit EGFR , both afatinib and neratinib have been assessed in lung cancer that has become resistant to gefitinib and erlotinib due to the T790M point mutation in the kinase domain .",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [153, 162],
        "tok_span": [34, 38]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [174, 179],
        "tok_span": [41, 45]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "erlotinib",
        "sbj_char_span": [174, 179],
        "obj_char_span": [153, 162],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [41, 45],
        "obj_tok_span": [34, 38]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "It is possible that the benefit seen among patients with K-Ras G13D mutants in response to cetuximab but not panitumumab is brought about in part by the ability of cetuximab to induce antibody dependent cellular cytotoxicity ( ADCC ) .",
    "entity_list": [
      {
        "name": "cetuximab",
        "ent_type": "drug",
        "char_span": [91, 100],
        "tok_span": [20, 24]
      },
      {
        "name": "G13D",
        "ent_type": "variant",
        "char_span": [63, 67],
        "tok_span": [13, 16]
      },
      {
        "name": "cetuximab",
        "ent_type": "drug",
        "char_span": [164, 173],
        "tok_span": [38, 42]
      }
    ],
    "relation_list": [
      {
        "subject": "G13D",
        "object": "cetuximab",
        "sbj_char_span": [63, 67],
        "obj_char_span": [91, 100],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [13, 16],
        "obj_tok_span": [20, 24]
      },
      {
        "subject": "G13D",
        "object": "cetuximab",
        "sbj_char_span": [63, 67],
        "obj_char_span": [164, 173],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [13, 16],
        "obj_tok_span": [38, 42]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Cetuximab-resistant PIK3CA and RAS cells isolated from control treated tumors in panel E were processed in parallel Cal27 cells infected with lentiviruses encoding PIK3CA H1047R or RAS G12V mutations .",
    "entity_list": [
      {
        "name": "Cetuximab-resistant",
        "ent_type": "drug",
        "char_span": [0, 19],
        "tok_span": [0, 5]
      },
      {
        "name": "H1047R",
        "ent_type": "variant",
        "char_span": [171, 177],
        "tok_span": [38, 42]
      }
    ],
    "relation_list": [
      {
        "subject": "H1047R",
        "object": "Cetuximab-resistant",
        "sbj_char_span": [171, 177],
        "obj_char_span": [0, 19],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [38, 42],
        "obj_tok_span": [0, 5]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "De Roock et al. demonstrated in a pooled analysis of 579 patients compiled from seven clinical trials examining metastatic colorectal cancer patients , that patients overall with KRAS mutation had decreased survival but those with KRAS G13D mutation had better overall survival and progression-free survival after treatment with cetuximab compared to other KRAS mutant tumors .",
    "entity_list": [
      {
        "name": "cetuximab",
        "ent_type": "drug",
        "char_span": [329, 338],
        "tok_span": [57, 61]
      },
      {
        "name": "G13D",
        "ent_type": "variant",
        "char_span": [236, 240],
        "tok_span": [41, 44]
      }
    ],
    "relation_list": [
      {
        "subject": "G13D",
        "object": "cetuximab",
        "sbj_char_span": [236, 240],
        "obj_char_span": [329, 338],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [41, 44],
        "obj_tok_span": [57, 61]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "In a multivariate analysis , patients with G13D mutation tumors treated with cetuximab had longer overall survival ( median , 7.6 months vs 5.7 months ) and longer progression-free survival ( median , 4.0 months vs 1.9 months ) than other KRAS mutant tumors . ",
    "entity_list": [
      {
        "name": "cetuximab",
        "ent_type": "drug",
        "char_span": [77, 86],
        "tok_span": [14, 18]
      },
      {
        "name": "G13D",
        "ent_type": "variant",
        "char_span": [43, 47],
        "tok_span": [7, 10]
      }
    ],
    "relation_list": [
      {
        "subject": "G13D",
        "object": "cetuximab",
        "sbj_char_span": [43, 47],
        "obj_char_span": [77, 86],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [7, 10],
        "obj_tok_span": [14, 18]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "T674I FIP1L1-PDGFRα is a “gatekeeper” mutation : substitution of the gatekeeper threonine ( T674 ) with a bulky amino acid ( I ) blocks access by imatinib and second-generation tyrosine kinase inhibitors ( TKIs ) , such as nilotinib and dasatinib , to a hydrophobic pocket inside the ATP binding site .",
    "entity_list": [
      {
        "name": "by imatinib",
        "ent_type": "drug",
        "char_span": [143, 154],
        "tok_span": [46, 49]
      },
      {
        "name": "T674I",
        "ent_type": "variant",
        "char_span": [0, 5],
        "tok_span": [0, 4]
      }
    ],
    "relation_list": [
      {
        "subject": "T674I",
        "object": "by imatinib",
        "sbj_char_span": [0, 5],
        "obj_char_span": [143, 154],
        "rel_type": "resistance",
        "sbj_tok_span": [0, 4],
        "obj_tok_span": [46, 49]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "To search for novel TKIs to overcome imatinib resistance , midostaurin , EXEL-0862 and sorafenib have been investigated both in vitro and in vivo in cells harboring T674I FIP1L1-PDGFRα .",
    "entity_list": [
      {
        "name": "imatinib",
        "ent_type": "drug",
        "char_span": [37, 45],
        "tok_span": [8, 10]
      },
      {
        "name": "T674I",
        "ent_type": "variant",
        "char_span": [165, 170],
        "tok_span": [37, 41]
      }
    ],
    "relation_list": [
      {
        "subject": "T674I",
        "object": "imatinib",
        "sbj_char_span": [165, 170],
        "obj_char_span": [37, 45],
        "rel_type": "resistance",
        "sbj_tok_span": [37, 41],
        "obj_tok_span": [8, 10]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "In contrast to imatinib , 300 nM ponatinib inhibited phosphorylation of T674I FIP1L1-PDGFRα to a similar degree as 1000 nM sorafenib ( Figure A ) .",
    "entity_list": [
      {
        "name": "imatinib",
        "ent_type": "drug",
        "char_span": [15, 23],
        "tok_span": [3, 5]
      },
      {
        "name": "T674I",
        "ent_type": "variant",
        "char_span": [72, 77],
        "tok_span": [15, 19]
      }
    ],
    "relation_list": [
      {
        "subject": "T674I",
        "object": "imatinib",
        "sbj_char_span": [72, 77],
        "obj_char_span": [15, 23],
        "rel_type": "resistance",
        "sbj_tok_span": [15, 19],
        "obj_tok_span": [3, 5]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Data indicated that crenolanib was significantly more potent than imatinib in inhibiting the kinase activity of imatinib-resistant mutated PDGFRα including D842I , D842V , D842Y , DI842-843IM , and deletion I843 .",
    "entity_list": [
      {
        "name": "imatinib",
        "ent_type": "drug",
        "char_span": [66, 74],
        "tok_span": [12, 14]
      },
      {
        "name": ", D842V",
        "ent_type": "variant",
        "char_span": [162, 169],
        "tok_span": [33, 38]
      },
      {
        "name": "imatinib-resistant",
        "ent_type": "drug",
        "char_span": [112, 130],
        "tok_span": [20, 24]
      }
    ],
    "relation_list": [
      {
        "subject": ", D842V",
        "object": "imatinib",
        "sbj_char_span": [162, 169],
        "obj_char_span": [66, 74],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [33, 38],
        "obj_tok_span": [12, 14]
      },
      {
        "subject": ", D842V",
        "object": "imatinib-resistant",
        "sbj_char_span": [162, 169],
        "obj_char_span": [112, 130],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [33, 38],
        "obj_tok_span": [20, 24]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "In one large series of 289 GISTs with PDGFRA mutations , 181 ( 63 percent ) had the imatinib-resistant substitution D842V .",
    "entity_list": [
      {
        "name": "imatinib-resistant",
        "ent_type": "drug",
        "char_span": [84, 102],
        "tok_span": [21, 25]
      },
      {
        "name": "D842V",
        "ent_type": "variant",
        "char_span": [116, 121],
        "tok_span": [26, 30]
      }
    ],
    "relation_list": [
      {
        "subject": "D842V",
        "object": "imatinib-resistant",
        "sbj_char_span": [116, 121],
        "obj_char_span": [84, 102],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [26, 30],
        "obj_tok_span": [21, 25]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "A biopsy by endorectal EUS is also recommended to screen for imatinib-resistant genotypes ( e.g. , WT GISTs , PDGFRα D842V mutation ) to avoid unnecessary drug related toxicity and ineffective therapy. , If EUS guided biopsy is not feasible , laparoscopic or open resection can be performed .",
    "entity_list": [
      {
        "name": "imatinib-resistant",
        "ent_type": "drug",
        "char_span": [61, 79],
        "tok_span": [13, 17]
      },
      {
        "name": "PDGFRα D842V",
        "ent_type": "variant",
        "char_span": [110, 122],
        "tok_span": [28, 35]
      }
    ],
    "relation_list": [
      {
        "subject": "PDGFRα D842V",
        "object": "imatinib-resistant",
        "sbj_char_span": [110, 122],
        "obj_char_span": [61, 79],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [28, 35],
        "obj_tok_span": [13, 17]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "For example , GIST with D842V mutation in PDGFRα exon 18 is known to be not responsive to imatinib .",
    "entity_list": [
      {
        "name": "to imatinib",
        "ent_type": "drug",
        "char_span": [87, 98],
        "tok_span": [23, 26]
      },
      {
        "name": "D842V",
        "ent_type": "variant",
        "char_span": [24, 29],
        "tok_span": [6, 10]
      }
    ],
    "relation_list": [
      {
        "subject": "D842V",
        "object": "to imatinib",
        "sbj_char_span": [24, 29],
        "obj_char_span": [87, 98],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [6, 10],
        "obj_tok_span": [23, 26]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "The L1196M mutation is hypothesized to induce steric interference of crizotinib binding similar to those in BCR-ABL and EGFR .",
    "entity_list": [
      {
        "name": "crizotinib",
        "ent_type": "drug",
        "char_span": [69, 79],
        "tok_span": [13, 17]
      },
      {
        "name": "L1196M",
        "ent_type": "variant",
        "char_span": [4, 10],
        "tok_span": [1, 5]
      }
    ],
    "relation_list": [
      {
        "subject": "L1196M",
        "object": "crizotinib",
        "sbj_char_span": [4, 10],
        "obj_char_span": [69, 79],
        "rel_type": "resistance",
        "sbj_tok_span": [1, 5],
        "obj_tok_span": [13, 17]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Although irreversible inhibitors of the EGFR such as dacomitinib or afatinib inhibit T790M in vitro their clinical activity in the setting of tumors with T790M mutations remains to be demonstrated and novel mutation specific T790M inhibitors are in clinical development .",
    "entity_list": [
      {
        "name": "afatinib",
        "ent_type": "drug",
        "char_span": [68, 76],
        "tok_span": [13, 15]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [85, 90],
        "tok_span": [16, 20]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "afatinib",
        "sbj_char_span": [85, 90],
        "obj_char_span": [68, 76],
        "rel_type": "response",
        "sbj_tok_span": [16, 20],
        "obj_tok_span": [13, 15]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Ponatinib BCR/ABL1 Philadelphia chromosome positive , BCR–ABL T315I mutation Indications and usage , warnings and precautions , adverse reactions , use in specific populations , clinical pharmacology , clinical studies",
    "entity_list": [
      {
        "name": "Ponatinib",
        "ent_type": "drug",
        "char_span": [0, 9],
        "tok_span": [0, 2]
      },
      {
        "name": "BCR–ABL T315I",
        "ent_type": "variant",
        "char_span": [54, 67],
        "tok_span": [11, 19]
      }
    ],
    "relation_list": [
      {
        "subject": "BCR–ABL T315I",
        "object": "Ponatinib",
        "sbj_char_span": [54, 67],
        "obj_char_span": [0, 9],
        "rel_type": "response",
        "sbj_tok_span": [11, 19],
        "obj_tok_span": [0, 2]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Ponatinib is a promising novel TKI active against the T315I BCR-ABL mutation , which confers resistance to currently available TKIs .",
    "entity_list": [
      {
        "name": "Ponatinib",
        "ent_type": "drug",
        "char_span": [0, 9],
        "tok_span": [0, 2]
      },
      {
        "name": "T315I",
        "ent_type": "variant",
        "char_span": [54, 59],
        "tok_span": [11, 15]
      }
    ],
    "relation_list": [
      {
        "subject": "T315I",
        "object": "Ponatinib",
        "sbj_char_span": [54, 59],
        "obj_char_span": [0, 9],
        "rel_type": "response",
        "sbj_tok_span": [11, 15],
        "obj_tok_span": [0, 2]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "E884K in-cis with L858R decreased erlotinib inhibition of AKT and STAT3 phosphorylation but increased inhibition by gefitinib .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [116, 125],
        "tok_span": [28, 32]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [18, 23],
        "tok_span": [8, 12]
      },
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [34, 43],
        "tok_span": [13, 17]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "gefitinib",
        "sbj_char_span": [18, 23],
        "obj_char_span": [116, 125],
        "rel_type": "sensitivity",
        "sbj_tok_span": [8, 12],
        "obj_tok_span": [28, 32]
      },
      {
        "subject": "L858R",
        "object": "erlotinib",
        "sbj_char_span": [18, 23],
        "obj_char_span": [34, 43],
        "rel_type": "sensitivity",
        "sbj_tok_span": [8, 12],
        "obj_tok_span": [13, 17]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Similarly , there was an opposite effect of the E884K mutation over L858R in-cis in inducing cellular cytotoxicity by erlotinib and gefitinib ( ) .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [132, 141],
        "tok_span": [32, 36]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [68, 73],
        "tok_span": [15, 19]
      },
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [118, 127],
        "tok_span": [27, 31]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "gefitinib",
        "sbj_char_span": [68, 73],
        "obj_char_span": [132, 141],
        "rel_type": "sensitivity",
        "sbj_tok_span": [15, 19],
        "obj_tok_span": [32, 36]
      },
      {
        "subject": "L858R",
        "object": "erlotinib",
        "sbj_char_span": [68, 73],
        "obj_char_span": [118, 127],
        "rel_type": "sensitivity",
        "sbj_tok_span": [15, 19],
        "obj_tok_span": [27, 31]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "E884K mutation of EGFR worked in concert with L858R to differentially alter sensitivity to EGFR kinase inhibitors erlotinib and gefitinib ( A ) Stable COS-7 transfects expressing the L858R and double mutant L858R+E884K variants of EGFR were used in the experiment .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [128, 137],
        "tok_span": [29, 33]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [46, 51],
        "tok_span": [12, 16]
      },
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [114, 123],
        "tok_span": [24, 28]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "gefitinib",
        "sbj_char_span": [46, 51],
        "obj_char_span": [128, 137],
        "rel_type": "sensitivity",
        "sbj_tok_span": [12, 16],
        "obj_tok_span": [29, 33]
      },
      {
        "subject": "L858R",
        "object": "erlotinib",
        "sbj_char_span": [46, 51],
        "obj_char_span": [114, 123],
        "rel_type": "sensitivity",
        "sbj_tok_span": [12, 16],
        "obj_tok_span": [24, 28]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "( C ) Relative expression of the apoptotic marker , cleaved-PARP ( Asp214 ) in L858R and L858R+E884K EGFR variants treated with increasing concentrations of erlotinib ( left ) and gefitinib ( right ) .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [180, 189],
        "tok_span": [48, 52]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [79, 84],
        "tok_span": [19, 23]
      },
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [157, 166],
        "tok_span": [40, 44]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "gefitinib",
        "sbj_char_span": [79, 84],
        "obj_char_span": [180, 189],
        "rel_type": "sensitivity",
        "sbj_tok_span": [19, 23],
        "obj_tok_span": [48, 52]
      },
      {
        "subject": "L858R",
        "object": "erlotinib",
        "sbj_char_span": [79, 84],
        "obj_char_span": [157, 166],
        "rel_type": "sensitivity",
        "sbj_tok_span": [19, 23],
        "obj_tok_span": [40, 44]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Disruption of the conserved Glu ( E ) 884-Arg ( R ) 958 salt bridge by a R958D substitution differentially altered L858R mutant receptor sensitivity to EGFR inhibitors ( A ) Stable COS-7 transfects expressing the sensitizing L858R and double mutant L858R+R958D variants of EGFR were cultured in 0.5 % BSA containing serum-free media for 16 hours , and then incubated with increasing concentrations of either erlotinib or gefitinib , in the presence of EGF stimulation ( 100 ng/ml ) .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [421, 430],
        "tok_span": [101, 105]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [115, 120],
        "tok_span": [29, 33]
      },
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [408, 417],
        "tok_span": [96, 100]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "gefitinib",
        "sbj_char_span": [115, 120],
        "obj_char_span": [421, 430],
        "rel_type": "sensitivity",
        "sbj_tok_span": [29, 33],
        "obj_tok_span": [101, 105]
      },
      {
        "subject": "L858R",
        "object": "erlotinib",
        "sbj_char_span": [115, 120],
        "obj_char_span": [408, 417],
        "rel_type": "sensitivity",
        "sbj_tok_span": [29, 33],
        "obj_tok_span": [96, 100]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "To this purpose we utilized 7 MPEDCC and as control a stable lung Adeno Ca cell lines , PC9 which is highly sensitive to gefitinib ( IC50 0,015 μM ) for the presence of exon 19 deletion , and its gefitinib resistance subclone PC9ZD , which harbors the gatekeeper T790M ( Table , ) .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [121, 130],
        "tok_span": [28, 32]
      },
      {
        "name": "gatekeeper T790M",
        "ent_type": "variant",
        "char_span": [252, 268],
        "tok_span": [68, 75]
      },
      {
        "name": "its gefitinib",
        "ent_type": "drug",
        "char_span": [192, 205],
        "tok_span": [51, 56]
      }
    ],
    "relation_list": [
      {
        "subject": "gatekeeper T790M",
        "object": "gefitinib",
        "sbj_char_span": [252, 268],
        "obj_char_span": [121, 130],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [68, 75],
        "obj_tok_span": [28, 32]
      },
      {
        "subject": "gatekeeper T790M",
        "object": "its gefitinib",
        "sbj_char_span": [252, 268],
        "obj_char_span": [192, 205],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [68, 75],
        "obj_tok_span": [51, 56]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Therapy of NSCLC with first generation small molecule EGFR kinase inhibitors , gefitinib and erlotinib , is severely limited by two main factors : first , the poor sensitivity to TKIs of tumor cells expressing wild type forms of the receptor ; second the emergence of drug resistance in virtually all tumors bearing EGFR mutations initially sensitive for the presence of either exon 19 deletions or exon 21 mutation L858R .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [79, 88],
        "tok_span": [12, 16]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [416, 421],
        "tok_span": [76, 80]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "gefitinib",
        "sbj_char_span": [416, 421],
        "obj_char_span": [79, 88],
        "rel_type": "sensitivity",
        "sbj_tok_span": [76, 80],
        "obj_tok_span": [12, 16]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Despite positive initial response , these patients almost invariably develop acquired secondary resistance , such as substitution of threonine 790 with methionine ( T790M ) , to these reversible inhibitors and relapse after several months , , , which accounts for about half of all cases of resistance to gefitinib and erlotinib , .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [305, 314],
        "tok_span": [55, 59]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [165, 170],
        "tok_span": [26, 30]
      },
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [319, 328],
        "tok_span": [60, 64]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "gefitinib",
        "sbj_char_span": [165, 170],
        "obj_char_span": [305, 314],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [26, 30],
        "obj_tok_span": [55, 59]
      },
      {
        "subject": "T790M",
        "object": "erlotinib",
        "sbj_char_span": [165, 170],
        "obj_char_span": [319, 328],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [26, 30],
        "obj_tok_span": [60, 64]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "The novel inhibitor CO-1686 showed promising results in NSCLC patients with the T790M EGFR mutation that were previously treated with the first-line EGFR inhibitor ( erlotinib or gefitinib ) ( NCT01526928 ) .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [179, 188],
        "tok_span": [38, 42]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [80, 85],
        "tok_span": [15, 19]
      },
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [166, 175],
        "tok_span": [33, 37]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "gefitinib",
        "sbj_char_span": [80, 85],
        "obj_char_span": [179, 188],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [15, 19],
        "obj_tok_span": [38, 42]
      },
      {
        "subject": "T790M",
        "object": "erlotinib",
        "sbj_char_span": [80, 85],
        "obj_char_span": [166, 175],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [15, 19],
        "obj_tok_span": [33, 37]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "These agents are irreversible inhibitors and covalently bind to Cys-797 of the EGFR ATP binding domain , and they seem to overcome resistance introduced by the T790M mutation that is seen with gefitinib and erlotinib .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [193, 202],
        "tok_span": [39, 43]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [160, 165],
        "tok_span": [30, 34]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "gefitinib",
        "sbj_char_span": [160, 165],
        "obj_char_span": [193, 202],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [30, 34],
        "obj_tok_span": [39, 43]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Another EGFR mutation , T790M in exon 20 , has been reported to be associated with resistance to gefitinib ( ; ) .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [97, 106],
        "tok_span": [21, 25]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [24, 29],
        "tok_span": [4, 8]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "gefitinib",
        "sbj_char_span": [24, 29],
        "obj_char_span": [97, 106],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [4, 8],
        "obj_tok_span": [21, 25]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "E884K mutation , when in-cis with L858R , significantly decreased the sensitivity of cell viability inhibition by erlotinib compared with L858R alone ;",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [114, 123],
        "tok_span": [25, 29]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [34, 39],
        "tok_span": [11, 15]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "erlotinib",
        "sbj_char_span": [34, 39],
        "obj_char_span": [114, 123],
        "rel_type": "sensitivity",
        "sbj_tok_span": [11, 15],
        "obj_tok_span": [25, 29]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "A second patient ( case # 5 , Table ) with two known EGFR-sensitive mutations ( L858R and G873E in exon 21 ) attained a PR ( 55 % decrease ) for 9+ months on erlotinib/cetuximab/bevacizumab .",
    "entity_list": [
      {
        "name": "erlotinib/cetuximab/bevacizumab",
        "ent_type": "drug",
        "char_span": [158, 189],
        "tok_span": [44, 56]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [80, 85],
        "tok_span": [18, 22]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "erlotinib/cetuximab/bevacizumab",
        "sbj_char_span": [80, 85],
        "obj_char_span": [158, 189],
        "rel_type": "sensitivity",
        "sbj_tok_span": [18, 22],
        "obj_tok_span": [44, 56]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "TP53 : Not done Yes PR 8.1 erlotinib , bortezomib SD 2 8 Adenocarcinoma T790M ( exon 20 ) , deletion in exon 19 Resistant , Sensitive PIK3CA : Not done",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [27, 36],
        "tok_span": [10, 14]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [72, 77],
        "tok_span": [25, 29]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "erlotinib",
        "sbj_char_span": [72, 77],
        "obj_char_span": [27, 36],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [25, 29],
        "obj_tok_span": [10, 14]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "−55 14 N L858R G873E E542K ND Erlotinib ( 13 months ) Y Y 8 N 200 Poorly-mod .",
    "entity_list": [
      {
        "name": "ND Erlotinib",
        "ent_type": "drug",
        "char_span": [27, 39],
        "tok_span": [16, 20]
      },
      {
        "name": "N L858R",
        "ent_type": "variant",
        "char_span": [7, 14],
        "tok_span": [3, 8]
      }
    ],
    "relation_list": [
      {
        "subject": "N L858R",
        "object": "ND Erlotinib",
        "sbj_char_span": [7, 14],
        "obj_char_span": [27, 39],
        "rel_type": "sensitivity",
        "sbj_tok_span": [3, 8],
        "obj_tok_span": [16, 20]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "In May 2013 FDA approved a companion diagnostic test for erlotinib ( Cobas ) that detects exon 19 deletions or exon 21 L858R substitutions .",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [57, 66],
        "tok_span": [10, 14]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [119, 124],
        "tok_span": [26, 30]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "erlotinib",
        "sbj_char_span": [119, 124],
        "obj_char_span": [57, 66],
        "rel_type": "sensitivity",
        "sbj_tok_span": [26, 30],
        "obj_tok_span": [10, 14]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "In preclinical studies , cell lines harboring the V842I mutation were resistant to trastuzumab , but were sensitive to irreversible HER2 inhibitor , neratinib .",
    "entity_list": [
      {
        "name": "trastuzumab",
        "ent_type": "drug",
        "char_span": [83, 94],
        "tok_span": [16, 19]
      },
      {
        "name": "V842I",
        "ent_type": "variant",
        "char_span": [50, 55],
        "tok_span": [8, 12]
      }
    ],
    "relation_list": [
      {
        "subject": "V842I",
        "object": "trastuzumab",
        "sbj_char_span": [50, 55],
        "obj_char_span": [83, 94],
        "rel_type": "sensitivity",
        "sbj_tok_span": [8, 12],
        "obj_tok_span": [16, 19]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "These results suggest that the T790M mutation may impair the ability of gefitinib or erlotinib to inhibit EGFR tyrosine kinase activity , even in EGFR mutants ( i.e. , L858R or an exon 19 deletion ) that are clinically associated with drug sensitivity .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [72, 81],
        "tok_span": [15, 19]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [31, 36],
        "tok_span": [5, 9]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [168, 173],
        "tok_span": [41, 45]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "gefitinib",
        "sbj_char_span": [31, 36],
        "obj_char_span": [72, 81],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [5, 9],
        "obj_tok_span": [15, 19]
      },
      {
        "subject": "L858R",
        "object": "gefitinib",
        "sbj_char_span": [168, 173],
        "obj_char_span": [72, 81],
        "rel_type": "sensitivity",
        "sbj_tok_span": [41, 45],
        "obj_tok_span": [15, 19]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Resistance of a NSCLC Cell Line Harboring Both T790M and L858R Mutations to Gefitinib or Erlotinib",
    "entity_list": [
      {
        "name": "Gefitinib",
        "ent_type": "drug",
        "char_span": [76, 85],
        "tok_span": [21, 24]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [47, 52],
        "tok_span": [10, 14]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [57, 62],
        "tok_span": [15, 19]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "Gefitinib",
        "sbj_char_span": [47, 52],
        "obj_char_span": [76, 85],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [10, 14],
        "obj_tok_span": [21, 24]
      },
      {
        "subject": "L858R",
        "object": "Gefitinib",
        "sbj_char_span": [57, 62],
        "obj_char_span": [76, 85],
        "rel_type": "sensitivity",
        "sbj_tok_span": [15, 19],
        "obj_tok_span": [21, 24]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "To further explore the functional consequences of the T790M mutation , we determined the sensitivity of various NSCLC cells lines grown in the presence of either gefitinib or erlotinib , using an assay based upon Calcein AM .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [162, 171],
        "tok_span": [29, 33]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [54, 59],
        "tok_span": [8, 12]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "gefitinib",
        "sbj_char_span": [54, 59],
        "obj_char_span": [162, 171],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [8, 12],
        "obj_tok_span": [29, 33]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "In tumors from patients not treated with either gefitinib or erlotinib , the 2369 C→T mutation ( T790M ) appears to be extremely rare . ",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [48, 57],
        "tok_span": [8, 12]
      },
      {
        "name": "( T790M",
        "ent_type": "variant",
        "char_span": [95, 102],
        "tok_span": [25, 30]
      }
    ],
    "relation_list": [
      {
        "subject": "( T790M",
        "object": "gefitinib",
        "sbj_char_span": [95, 102],
        "obj_char_span": [48, 57],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [25, 30],
        "obj_tok_span": [8, 12]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "In either scenario , treatment with gefitinib or erlotinib subsequently allows these resistant subclones to become apparent , because most cells bearing sensitivity conferring mutations die , while cells with the T790M mutation persist .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [36, 45],
        "tok_span": [6, 10]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [213, 218],
        "tok_span": [39, 43]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "gefitinib",
        "sbj_char_span": [213, 218],
        "obj_char_span": [36, 45],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [39, 43],
        "obj_tok_span": [6, 10]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Consistent with this , the H1975 NSCLC cell line reported here to contain both T790M and L858R did not to our knowledge undergo any prior treatment with gefitinib or erlotinib ; the doubly mutated cells must have become dominant over time through multiple passages in vitro .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [153, 162],
        "tok_span": [35, 39]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [79, 84],
        "tok_span": [16, 20]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [89, 94],
        "tok_span": [21, 25]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "gefitinib",
        "sbj_char_span": [79, 84],
        "obj_char_span": [153, 162],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [16, 20],
        "obj_tok_span": [35, 39]
      },
      {
        "subject": "L858R",
        "object": "gefitinib",
        "sbj_char_span": [89, 94],
        "obj_char_span": [153, 162],
        "rel_type": "sensitivity",
        "sbj_tok_span": [21, 25],
        "obj_tok_span": [35, 39]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "EGFR mutation status including wild-type ( WT ) , E746-A750 del ( del ) , L858R and T790M was determined by both IHC and RNA-LNA PCR clamp assays with 11 clinical samples of cancer patients refractory to gefitinib treatment .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [204, 213],
        "tok_span": [54, 58]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [84, 89],
        "tok_span": [28, 32]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [74, 79],
        "tok_span": [23, 27]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "gefitinib",
        "sbj_char_span": [84, 89],
        "obj_char_span": [204, 213],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [28, 32],
        "obj_tok_span": [54, 58]
      },
      {
        "subject": "L858R",
        "object": "gefitinib",
        "sbj_char_span": [74, 79],
        "obj_char_span": [204, 213],
        "rel_type": "sensitivity",
        "sbj_tok_span": [23, 27],
        "obj_tok_span": [54, 58]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "In this present study , erlotinib- and gefitinib-resistant cell lines were established from two human lung cancer cell lines , PC9 cells harboring delE746-A750 mutation and 11–18 cells harboring L858R mutation , respectively .",
    "entity_list": [
      {
        "name": "gefitinib-resistant",
        "ent_type": "drug",
        "char_span": [39, 58],
        "tok_span": [11, 17]
      },
      {
        "name": "harboring L858R",
        "ent_type": "variant",
        "char_span": [185, 200],
        "tok_span": [47, 52]
      }
    ],
    "relation_list": [
      {
        "subject": "harboring L858R",
        "object": "gefitinib-resistant",
        "sbj_char_span": [185, 200],
        "obj_char_span": [39, 58],
        "rel_type": "sensitivity",
        "sbj_tok_span": [47, 52],
        "obj_tok_span": [11, 17]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Establishment of Erlotinib- and Gefitinib-resistant Cell Lines from PC9 and 11–18 Cells To isolate erlotinib-resistant cell lines from PC9 cells harboring delE746-A750 , and from 11–18 cells harboring L858R , both cell lines were cultured in stepwise increasing doses of erlotinib from 0.05 to 10 µM , for approximately 6 months , as described previously .",
    "entity_list": [
      {
        "name": "Gefitinib-resistant",
        "ent_type": "drug",
        "char_span": [32, 51],
        "tok_span": [9, 14]
      },
      {
        "name": "harboring L858R",
        "ent_type": "variant",
        "char_span": [191, 206],
        "tok_span": [55, 60]
      }
    ],
    "relation_list": [
      {
        "subject": "harboring L858R",
        "object": "Gefitinib-resistant",
        "sbj_char_span": [191, 206],
        "obj_char_span": [32, 51],
        "rel_type": "sensitivity",
        "sbj_tok_span": [55, 60],
        "obj_tok_span": [9, 14]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Consistent with the increased sensitivity to gefitinib and erlotinib of patient tumors harboring the missense mutations or exon 19 deletions , anchorage independent growth of cells expressing L858R , G719S , or L747_E749del A750P was inhibited by 100 nM erlotinib ( A and B ) or gefitinib ( B and unpublished data ) , although the G719S mutant may be somewhat more resistant to gefitinib ( A and unpublished data ) , consistent with other in vitro studies .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [45, 54],
        "tok_span": [6, 10]
      },
      {
        "name": "G719S",
        "ent_type": "variant",
        "char_span": [200, 205],
        "tok_span": [40, 44]
      },
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [279, 288],
        "tok_span": [73, 77]
      },
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [378, 387],
        "tok_span": [97, 101]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [192, 197],
        "tok_span": [35, 39]
      }
    ],
    "relation_list": [
      {
        "subject": "G719S",
        "object": "gefitinib",
        "sbj_char_span": [200, 205],
        "obj_char_span": [45, 54],
        "rel_type": "sensitivity",
        "sbj_tok_span": [40, 44],
        "obj_tok_span": [6, 10]
      },
      {
        "subject": "G719S",
        "object": "gefitinib",
        "sbj_char_span": [200, 205],
        "obj_char_span": [279, 288],
        "rel_type": "sensitivity",
        "sbj_tok_span": [40, 44],
        "obj_tok_span": [73, 77]
      },
      {
        "subject": "G719S",
        "object": "gefitinib",
        "sbj_char_span": [200, 205],
        "obj_char_span": [378, 387],
        "rel_type": "sensitivity",
        "sbj_tok_span": [40, 44],
        "obj_tok_span": [97, 101]
      },
      {
        "subject": "L858R",
        "object": "gefitinib",
        "sbj_char_span": [192, 197],
        "obj_char_span": [45, 54],
        "rel_type": "sensitivity",
        "sbj_tok_span": [35, 39],
        "obj_tok_span": [6, 10]
      },
      {
        "subject": "L858R",
        "object": "gefitinib",
        "sbj_char_span": [192, 197],
        "obj_char_span": [279, 288],
        "rel_type": "sensitivity",
        "sbj_tok_span": [35, 39],
        "obj_tok_span": [73, 77]
      },
      {
        "subject": "L858R",
        "object": "gefitinib",
        "sbj_char_span": [192, 197],
        "obj_char_span": [378, 387],
        "rel_type": "sensitivity",
        "sbj_tok_span": [35, 39],
        "obj_tok_span": [97, 101]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Transformation by cells expressing the L858R EGFR was inhibited by 0.1 μM gefitinib or erlotinib , whereas transformation by cells expressing the insertion mutant was resistant to low concentrations of these inhibitors .",
    "entity_list": [
      {
        "name": "μM gefitinib",
        "ent_type": "drug",
        "char_span": [71, 83],
        "tok_span": [16, 22]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [39, 44],
        "tok_span": [5, 9]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "μM gefitinib",
        "sbj_char_span": [39, 44],
        "obj_char_span": [71, 83],
        "rel_type": "sensitivity",
        "sbj_tok_span": [5, 9],
        "obj_tok_span": [16, 22]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "To overcome such drug resistance , novel mutant-selective EGFR kinase inhibitors against EGFR T790M were reported , and 4-pyrrylamino quinazolines as new gefitinib analogues were synthesized .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [154, 163],
        "tok_span": [34, 38]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [94, 99],
        "tok_span": [15, 19]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "gefitinib",
        "sbj_char_span": [94, 99],
        "obj_char_span": [154, 163],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [15, 19],
        "obj_tok_span": [34, 38]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "In this study , we design , synthesize and evaluated a number of novel quinazoline derivatives by exchanging the positions of the C5 and C6 substituents and varying the C4-amino functionality of gefitinib , and report that compound V1801 having a trifluoromethyl group at the C5'-position and a bromine at the C2'-position of the aniline moiety substituted at the C4 position of quinazoline core overcomes gefitinib resistance via up-regulation of Noxa , suggesting a novel strategy to fight against NSCLC with EGFR T790M mutation .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [195, 204],
        "tok_span": [41, 45]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [516, 521],
        "tok_span": [120, 124]
      },
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [406, 415],
        "tok_span": [96, 100]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "gefitinib",
        "sbj_char_span": [516, 521],
        "obj_char_span": [195, 204],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [120, 124],
        "obj_tok_span": [41, 45]
      },
      {
        "subject": "T790M",
        "object": "gefitinib",
        "sbj_char_span": [516, 521],
        "obj_char_span": [406, 415],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [120, 124],
        "obj_tok_span": [96, 100]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "However , Yun et al. ( 2008 ) showed that both the single T790M mutant and the double-mutant L858R/T790M maintain the same low nanomolar affinity for gefitinib as the L858R mutant .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [150, 159],
        "tok_span": [41, 45]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [58, 63],
        "tok_span": [14, 18]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [167, 172],
        "tok_span": [47, 51]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "gefitinib",
        "sbj_char_span": [58, 63],
        "obj_char_span": [150, 159],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [14, 18],
        "obj_tok_span": [41, 45]
      },
      {
        "subject": "L858R",
        "object": "gefitinib",
        "sbj_char_span": [167, 172],
        "obj_char_span": [150, 159],
        "rel_type": "sensitivity",
        "sbj_tok_span": [47, 51],
        "obj_tok_span": [41, 45]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Recent report by Yoshikawa , S. et al. ( 2013 ) demonstrated the acquired resistant of double mutant G719S/T790M (DM) to gefitinib , G719S mutation occurs within the phosphate binding loop ( P-loop ) and not observed frequently .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [121, 130],
        "tok_span": [34, 38]
      },
      {
        "name": "G719S",
        "ent_type": "variant",
        "char_span": [133, 138],
        "tok_span": [39, 43]
      }
    ],
    "relation_list": [
      {
        "subject": "G719S",
        "object": "gefitinib",
        "sbj_char_span": [133, 138],
        "obj_char_span": [121, 130],
        "rel_type": "sensitivity",
        "sbj_tok_span": [39, 43],
        "obj_tok_span": [34, 38]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "On the other hand , the increased inhibition potency for Gefitinib against EGFR L858R mutant ( compared to EGFR WT protein ) and subsequent further increase in potency for Gefitinib against the EGFR L858R + E884K double mutant correlates well with the increased global connectivity of the hub residues in the mutants ( – wild type , – L858R , – L858R + E884K ) .",
    "entity_list": [
      {
        "name": "Gefitinib",
        "ent_type": "drug",
        "char_span": [57, 66],
        "tok_span": [10, 13]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [80, 85],
        "tok_span": [15, 19]
      },
      {
        "name": "Gefitinib",
        "ent_type": "drug",
        "char_span": [172, 181],
        "tok_span": [34, 37]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "Gefitinib",
        "sbj_char_span": [80, 85],
        "obj_char_span": [57, 66],
        "rel_type": "sensitivity",
        "sbj_tok_span": [15, 19],
        "obj_tok_span": [10, 13]
      },
      {
        "subject": "L858R",
        "object": "Gefitinib",
        "sbj_char_span": [80, 85],
        "obj_char_span": [172, 181],
        "rel_type": "sensitivity",
        "sbj_tok_span": [15, 19],
        "obj_tok_span": [34, 37]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "However , three additional patients with clinical resistance to gefitinib or erlotinib did not have the T790M mutation , nor did they have mutant KRAS alleles that have previously been shown by these same authors to confer resistance to these inhibitors .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [64, 73],
        "tok_span": [9, 13]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [104, 109],
        "tok_span": [22, 26]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "gefitinib",
        "sbj_char_span": [104, 109],
        "obj_char_span": [64, 73],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [22, 26],
        "obj_tok_span": [9, 13]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "The T790M mutation accounts for approximately 50 % of cases in which acquired resistance to erlotinib or gefitinib occurs , , .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [105, 114],
        "tok_span": [23, 27]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [4, 9],
        "tok_span": [1, 5]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "gefitinib",
        "sbj_char_span": [4, 9],
        "obj_char_span": [105, 114],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [1, 5],
        "obj_tok_span": [23, 27]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "T790M and MET amplification account for approximately 60–70 % of all known causes of acquired resistance to gefitinib or erlotinib ; these amplifications are not mutually exclusive and can be detected in the same resistant tumor or may occur independently in different metastatic sites in the same patient .",
    "entity_list": [
      {
        "name": "to gefitinib",
        "ent_type": "drug",
        "char_span": [105, 117],
        "tok_span": [21, 26]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [0, 5],
        "tok_span": [0, 4]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "to gefitinib",
        "sbj_char_span": [0, 5],
        "obj_char_span": [105, 117],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [0, 4],
        "obj_tok_span": [21, 26]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "This report strengthens the evidence of T790M as an acquired gefitinib-resistant mutation .",
    "entity_list": [
      {
        "name": "gefitinib-resistant",
        "ent_type": "drug",
        "char_span": [61, 80],
        "tok_span": [14, 20]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [40, 45],
        "tok_span": [7, 11]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "gefitinib-resistant",
        "sbj_char_span": [40, 45],
        "obj_char_span": [61, 80],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [7, 11],
        "obj_tok_span": [14, 20]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "A non-small-cell lung cancer cell line bearing both T790M and L858R mutations was approximately 100-fold less sensitive to gefitinib or erlotinib , and did not show inhibition of tyrosine phosphorylation in vitro .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [123, 132],
        "tok_span": [30, 34]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [52, 57],
        "tok_span": [12, 16]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [62, 67],
        "tok_span": [17, 21]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "gefitinib",
        "sbj_char_span": [52, 57],
        "obj_char_span": [123, 132],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [12, 16],
        "obj_tok_span": [30, 34]
      },
      {
        "subject": "L858R",
        "object": "gefitinib",
        "sbj_char_span": [62, 67],
        "obj_char_span": [123, 132],
        "rel_type": "sensitivity",
        "sbj_tok_span": [17, 21],
        "obj_tok_span": [30, 34]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "( B ) Drugs such as the 4-anilinoquinazolines gefitinib ( Iressa ) and erlotinib ( Tarceva ) can inhibit the activity of EGFR L858R mutant .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [46, 55],
        "tok_span": [14, 18]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [126, 131],
        "tok_span": [39, 43]
      },
      {
        "name": "Iressa",
        "ent_type": "drug",
        "char_span": [58, 64],
        "tok_span": [19, 22]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "gefitinib",
        "sbj_char_span": [126, 131],
        "obj_char_span": [46, 55],
        "rel_type": "sensitivity",
        "sbj_tok_span": [39, 43],
        "obj_tok_span": [14, 18]
      },
      {
        "subject": "L858R",
        "object": "Iressa",
        "sbj_char_span": [126, 131],
        "obj_char_span": [58, 64],
        "rel_type": "sensitivity",
        "sbj_tok_span": [39, 43],
        "obj_tok_span": [19, 22]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Further studies of gefitinib revealed that this 4-anilinoquinazoline inhibitor , structurally similar to erlotinib , binds the EGFR c.2573T & gt ; G ( L858R ) mutant with a 20-fold higher affinity compared to the wild-type enzyme . ",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [19, 28],
        "tok_span": [3, 7]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [151, 156],
        "tok_span": [41, 45]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "gefitinib",
        "sbj_char_span": [151, 156],
        "obj_char_span": [19, 28],
        "rel_type": "sensitivity",
        "sbj_tok_span": [41, 45],
        "obj_tok_span": [3, 7]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "The T790M mutation results in alteration of the topology of the ATP binding pocket not only interrupting the physicochemical binding of gefitinib/erlotinib , but also leading to much increased affinity of the EGFR protein to ATP resulting in resistance to EGFR-TKIs .",
    "entity_list": [
      {
        "name": "gefitinib/erlotinib",
        "ent_type": "drug",
        "char_span": [136, 155],
        "tok_span": [25, 34]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [4, 9],
        "tok_span": [1, 5]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "gefitinib/erlotinib",
        "sbj_char_span": [4, 9],
        "obj_char_span": [136, 155],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [1, 5],
        "obj_tok_span": [25, 34]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "PC9GR cells ( gefitinib resistant ) were shown to harbor a secondary T790M mutation in EGFR , whereas HCC827ER cells ( erlotinib resistant ) demonstrated MET overexpression , as previously reported ( ) .",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [119, 128],
        "tok_span": [32, 36]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [69, 74],
        "tok_span": [17, 21]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "erlotinib",
        "sbj_char_span": [69, 74],
        "obj_char_span": [119, 128],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [17, 21],
        "obj_tok_span": [32, 36]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Six patients had EGFR T790M resistance mutation identified after treatment with erlotinib ( Supporting Table ; see online supporting information ) .",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [80, 89],
        "tok_span": [14, 18]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [22, 27],
        "tok_span": [4, 8]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "erlotinib",
        "sbj_char_span": [22, 27],
        "obj_char_span": [80, 89],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [4, 8],
        "obj_tok_span": [14, 18]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "T790M status was unknown in 54 patients who had biopsies taken prior to progression on erlotinib .",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [87, 96],
        "tok_span": [18, 22]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [0, 5],
        "tok_span": [0, 4]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "erlotinib",
        "sbj_char_span": [0, 5],
        "obj_char_span": [87, 96],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [0, 4],
        "obj_tok_span": [18, 22]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "An experiment using cell lines transfected concurrently with activating mutations and a T790M mutation also proved that resistance to gefitinib and erlotinib is evident when this mutation is present .",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [148, 157],
        "tok_span": [27, 31]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [88, 93],
        "tok_span": [12, 16]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "erlotinib",
        "sbj_char_span": [88, 93],
        "obj_char_span": [148, 157],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [12, 16],
        "obj_tok_span": [27, 31]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Erlotinib is particularly effective in cancers in which the EGFR kinase domain contains activating mutations , the two most common of which are Δ746–750 and L858R– .",
    "entity_list": [
      {
        "name": "Erlotinib",
        "ent_type": "drug",
        "char_span": [0, 9],
        "tok_span": [0, 3]
      },
      {
        "name": "and L858R–",
        "ent_type": "variant",
        "char_span": [153, 163],
        "tok_span": [30, 36]
      }
    ],
    "relation_list": [
      {
        "subject": "and L858R–",
        "object": "Erlotinib",
        "sbj_char_span": [153, 163],
        "obj_char_span": [0, 9],
        "rel_type": "sensitivity",
        "sbj_tok_span": [30, 36],
        "obj_tok_span": [0, 3]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Addition of erlotinib to the cell culture media allowed for the purification of ~0.1 mg of L858R and Δ746–750 tEGFRs per liter of cell culture .",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [12, 21],
        "tok_span": [2, 6]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [91, 96],
        "tok_span": [22, 26]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "erlotinib",
        "sbj_char_span": [91, 96],
        "obj_char_span": [12, 21],
        "rel_type": "sensitivity",
        "sbj_tok_span": [22, 26],
        "obj_tok_span": [2, 6]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "In contrast to the behavior of erlotinib , the L858R and Δ746–750 tEGFR forms were highly resistant to lapatinib with apparent Kis in the range of 2–6 µM .",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [31, 40],
        "tok_span": [6, 10]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [47, 52],
        "tok_span": [12, 16]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "erlotinib",
        "sbj_char_span": [47, 52],
        "obj_char_span": [31, 40],
        "rel_type": "sensitivity",
        "sbj_tok_span": [12, 16],
        "obj_tok_span": [6, 10]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Most NSCLC patients who harbor activating EGFR mutations , including deletions in exon 19 or the point mutation L858R in exon 21 , experience an initial marked response to the EGFR-TKIs gefitinib or erlotinib . ",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [199, 208],
        "tok_span": [42, 46]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [112, 117],
        "tok_span": [18, 22]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "erlotinib",
        "sbj_char_span": [112, 117],
        "obj_char_span": [199, 208],
        "rel_type": "sensitivity",
        "sbj_tok_span": [18, 22],
        "obj_tok_span": [42, 46]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Further , patients with nonsmall cell lung cancer who initially responded to erlotinib or gefitinib therapy showed progression after a median of 12–13 months. , After patients developed acquired resistance confirmed on medical imaging , continuing use of erlotinib or gefitinib would lead to a surge in the rate of EGFR T790M mutation which , in vitro , conferred resistance to treatment with erlotinib and gefitinib .",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [77, 86],
        "tok_span": [14, 18]
      },
      {
        "name": "EGFR T790M",
        "ent_type": "variant",
        "char_span": [315, 325],
        "tok_span": [67, 72]
      },
      {
        "name": "of erlotinib",
        "ent_type": "drug",
        "char_span": [252, 264],
        "tok_span": [48, 53]
      },
      {
        "name": "with erlotinib",
        "ent_type": "drug",
        "char_span": [388, 402],
        "tok_span": [83, 88]
      }
    ],
    "relation_list": [
      {
        "subject": "EGFR T790M",
        "object": "erlotinib",
        "sbj_char_span": [315, 325],
        "obj_char_span": [77, 86],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [67, 72],
        "obj_tok_span": [14, 18]
      },
      {
        "subject": "EGFR T790M",
        "object": "of erlotinib",
        "sbj_char_span": [315, 325],
        "obj_char_span": [252, 264],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [67, 72],
        "obj_tok_span": [48, 53]
      },
      {
        "subject": "EGFR T790M",
        "object": "with erlotinib",
        "sbj_char_span": [315, 325],
        "obj_char_span": [388, 402],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [67, 72],
        "obj_tok_span": [83, 88]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Second-generation EGFR TKIs – such as neratinib , afatinib and dacomitinib – are effective in preclinical gefitinib- and erlotinib-resistant EGFR T790M models , but to date their delivery in EGFR TKI-resistant patients have shown disappointing results in the clinic .",
    "entity_list": [
      {
        "name": "and erlotinib-resistant",
        "ent_type": "drug",
        "char_span": [117, 140],
        "tok_span": [31, 38]
      },
      {
        "name": "EGFR T790M",
        "ent_type": "variant",
        "char_span": [141, 151],
        "tok_span": [38, 43]
      }
    ],
    "relation_list": [
      {
        "subject": "EGFR T790M",
        "object": "and erlotinib-resistant",
        "sbj_char_span": [141, 151],
        "obj_char_span": [117, 140],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [38, 43],
        "obj_tok_span": [31, 38]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "What is remarkable is that the H1975 cell line harbors the T790M and L858R mutations in the HER1 gene ( information obtained from the Sanger Institute website ) , which confer resistance to HER1 kinase inhibitors , Gefitinib and Erlotinib , responded to the irreversible HER1 kinase inhibitor BIBW-2992 . ",
    "entity_list": [
      {
        "name": "Erlotinib",
        "ent_type": "drug",
        "char_span": [229, 238],
        "tok_span": [53, 56]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [69, 74],
        "tok_span": [19, 23]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [59, 64],
        "tok_span": [14, 18]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "Erlotinib",
        "sbj_char_span": [69, 74],
        "obj_char_span": [229, 238],
        "rel_type": "sensitivity",
        "sbj_tok_span": [19, 23],
        "obj_tok_span": [53, 56]
      },
      {
        "subject": "T790M",
        "object": "Erlotinib",
        "sbj_char_span": [59, 64],
        "obj_char_span": [229, 238],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [14, 18],
        "obj_tok_span": [53, 56]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "The T790M EGFR mutant has increased affinity for ATP , which is the primary mechanism responsible for the development of resistance to small molecule tyrosine kinase inhibitors ( TKIs ) , such as gefitinib and erlotinib .",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [210, 219],
        "tok_span": [42, 46]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [4, 9],
        "tok_span": [1, 5]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "erlotinib",
        "sbj_char_span": [4, 9],
        "obj_char_span": [210, 219],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [1, 5],
        "obj_tok_span": [42, 46]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Although several previous studies have suggested that tumors harboring mutations in the EGFR kinase domain were sensitive to TKIs such as gefitinib or erlotinib , others had reported an association between the T790M mutation in exon 20 and the resistance to TKIs .",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [151, 160],
        "tok_span": [27, 31]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [210, 215],
        "tok_span": [39, 43]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "erlotinib",
        "sbj_char_span": [210, 215],
        "obj_char_span": [151, 160],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [39, 43],
        "obj_tok_span": [27, 31]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "The effects of imatinib on c-Kit expression were analyzed in the murine BaF-3 cell line transfected with human T670I c-Kit mutant or wt-c-Kit .",
    "entity_list": [
      {
        "name": "imatinib",
        "ent_type": "drug",
        "char_span": [15, 23],
        "tok_span": [3, 5]
      },
      {
        "name": "T670I",
        "ent_type": "variant",
        "char_span": [111, 116],
        "tok_span": [24, 28]
      }
    ],
    "relation_list": [
      {
        "subject": "T670I",
        "object": "imatinib",
        "sbj_char_span": [111, 116],
        "obj_char_span": [15, 23],
        "rel_type": "resistance",
        "sbj_tok_span": [24, 28],
        "obj_tok_span": [3, 5]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "As shown in , internalization of Kit by imatinib was detected in UT-7/Epo and wt-c-Kit BaF3 cells , but not in the T670I c-Kit mutant BaF-3 cells .",
    "entity_list": [
      {
        "name": "imatinib",
        "ent_type": "drug",
        "char_span": [40, 48],
        "tok_span": [8, 10]
      },
      {
        "name": "T670I",
        "ent_type": "variant",
        "char_span": [115, 120],
        "tok_span": [34, 38]
      }
    ],
    "relation_list": [
      {
        "subject": "T670I",
        "object": "imatinib",
        "sbj_char_span": [115, 120],
        "obj_char_span": [40, 48],
        "rel_type": "resistance",
        "sbj_tok_span": [34, 38],
        "obj_tok_span": [8, 10]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Acquired resistance EGFR mutations Mutations in the EC domain ( S492R ) and in the kinase domain ( codons 714 and 794 ) of EGFR found in patients Panitumumab remained active in a patient with S492R mutation , which abrogated cetuximab binding .",
    "entity_list": [
      {
        "name": "Panitumumab",
        "ent_type": "drug",
        "char_span": [146, 157],
        "tok_span": [34, 37]
      },
      {
        "name": "S492R",
        "ent_type": "variant",
        "char_span": [64, 69],
        "tok_span": [11, 15]
      }
    ],
    "relation_list": [
      {
        "subject": "S492R",
        "object": "Panitumumab",
        "sbj_char_span": [64, 69],
        "obj_char_span": [146, 157],
        "rel_type": "response",
        "sbj_tok_span": [11, 15],
        "obj_tok_span": [34, 37]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "S1206Y EML-ALKpm Lowers crizotinib-protein affinity by eliminating two H-bonds between crizotinib and the ALK binding site",
    "entity_list": [
      {
        "name": "crizotinib-protein",
        "ent_type": "drug",
        "char_span": [24, 42],
        "tok_span": [12, 18]
      },
      {
        "name": "S1206Y",
        "ent_type": "variant",
        "char_span": [0, 6],
        "tok_span": [0, 4]
      },
      {
        "name": "crizotinib",
        "ent_type": "drug",
        "char_span": [87, 97],
        "tok_span": [26, 30]
      }
    ],
    "relation_list": [
      {
        "subject": "S1206Y",
        "object": "crizotinib-protein",
        "sbj_char_span": [0, 6],
        "obj_char_span": [24, 42],
        "rel_type": "resistance",
        "sbj_tok_span": [0, 4],
        "obj_tok_span": [12, 18]
      },
      {
        "subject": "S1206Y",
        "object": "crizotinib",
        "sbj_char_span": [0, 6],
        "obj_char_span": [87, 97],
        "rel_type": "resistance",
        "sbj_tok_span": [0, 4],
        "obj_tok_span": [26, 30]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "G1269A EML-ALKpm Gly→Ala reduces crizotinib binding ATP binding pocket by steric hindrance",
    "entity_list": [
      {
        "name": "reduces crizotinib",
        "ent_type": "drug",
        "char_span": [25, 43],
        "tok_span": [13, 18]
      },
      {
        "name": "G1269A",
        "ent_type": "variant",
        "char_span": [0, 6],
        "tok_span": [0, 4]
      }
    ],
    "relation_list": [
      {
        "subject": "G1269A",
        "object": "reduces crizotinib",
        "sbj_char_span": [0, 6],
        "obj_char_span": [25, 43],
        "rel_type": "resistance",
        "sbj_tok_span": [0, 4],
        "obj_tok_span": [13, 18]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "C1156Y EML-ALKpm Alters ALK crizotinib binding cavity , reducing crizotinib-protein interactions",
    "entity_list": [
      {
        "name": "crizotinib",
        "ent_type": "drug",
        "char_span": [28, 38],
        "tok_span": [14, 18]
      },
      {
        "name": "C1156Y",
        "ent_type": "variant",
        "char_span": [0, 6],
        "tok_span": [0, 4]
      },
      {
        "name": "crizotinib-protein",
        "ent_type": "drug",
        "char_span": [65, 83],
        "tok_span": [22, 28]
      }
    ],
    "relation_list": [
      {
        "subject": "C1156Y",
        "object": "crizotinib",
        "sbj_char_span": [0, 6],
        "obj_char_span": [28, 38],
        "rel_type": "resistance",
        "sbj_tok_span": [0, 4],
        "obj_tok_span": [14, 18]
      },
      {
        "subject": "C1156Y",
        "object": "crizotinib-protein",
        "sbj_char_span": [0, 6],
        "obj_char_span": [65, 83],
        "rel_type": "resistance",
        "sbj_tok_span": [0, 4],
        "obj_tok_span": [22, 28]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "We utilised three complexes , namely , native ( ALK-crizotinib ) , F1174L ( ALK F1174L-crizotinib ) , and R1275Q ( ALK R1275Q-crizotinib ) for our analysis .",
    "entity_list": [
      {
        "name": "ALK-crizotinib",
        "ent_type": "drug",
        "char_span": [48, 62],
        "tok_span": [10, 17]
      },
      {
        "name": "F1174L",
        "ent_type": "variant",
        "char_span": [67, 73],
        "tok_span": [19, 23]
      },
      {
        "name": "F1174L-crizotinib",
        "ent_type": "drug",
        "char_span": [80, 97],
        "tok_span": [26, 35]
      },
      {
        "name": "R1275Q-crizotinib",
        "ent_type": "drug",
        "char_span": [119, 136],
        "tok_span": [45, 54]
      },
      {
        "name": "R1275Q",
        "ent_type": "variant",
        "char_span": [106, 112],
        "tok_span": [38, 42]
      }
    ],
    "relation_list": [
      {
        "subject": "F1174L",
        "object": "ALK-crizotinib",
        "sbj_char_span": [67, 73],
        "obj_char_span": [48, 62],
        "rel_type": "resistance",
        "sbj_tok_span": [19, 23],
        "obj_tok_span": [10, 17]
      },
      {
        "subject": "F1174L",
        "object": "F1174L-crizotinib",
        "sbj_char_span": [67, 73],
        "obj_char_span": [80, 97],
        "rel_type": "resistance",
        "sbj_tok_span": [19, 23],
        "obj_tok_span": [26, 35]
      },
      {
        "subject": "F1174L",
        "object": "R1275Q-crizotinib",
        "sbj_char_span": [67, 73],
        "obj_char_span": [119, 136],
        "rel_type": "resistance",
        "sbj_tok_span": [19, 23],
        "obj_tok_span": [45, 54]
      },
      {
        "subject": "R1275Q",
        "object": "ALK-crizotinib",
        "sbj_char_span": [106, 112],
        "obj_char_span": [48, 62],
        "rel_type": "sensitivity",
        "sbj_tok_span": [38, 42],
        "obj_tok_span": [10, 17]
      },
      {
        "subject": "R1275Q",
        "object": "F1174L-crizotinib",
        "sbj_char_span": [106, 112],
        "obj_char_span": [80, 97],
        "rel_type": "sensitivity",
        "sbj_tok_span": [38, 42],
        "obj_tok_span": [26, 35]
      },
      {
        "subject": "R1275Q",
        "object": "R1275Q-crizotinib",
        "sbj_char_span": [106, 112],
        "obj_char_span": [119, 136],
        "rel_type": "sensitivity",
        "sbj_tok_span": [38, 42],
        "obj_tok_span": [45, 54]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "In 2010 , Choi et al. identified two secondary mutations ( C1156Y and L1196M ) within the kinase domain of ALK fusion protein , which confer marked crizotinib resistance .",
    "entity_list": [
      {
        "name": "crizotinib",
        "ent_type": "drug",
        "char_span": [148, 158],
        "tok_span": [35, 39]
      },
      {
        "name": "L1196M",
        "ent_type": "variant",
        "char_span": [70, 76],
        "tok_span": [17, 21]
      },
      {
        "name": "C1156Y",
        "ent_type": "variant",
        "char_span": [59, 65],
        "tok_span": [12, 16]
      }
    ],
    "relation_list": [
      {
        "subject": "L1196M",
        "object": "crizotinib",
        "sbj_char_span": [70, 76],
        "obj_char_span": [148, 158],
        "rel_type": "resistance",
        "sbj_tok_span": [17, 21],
        "obj_tok_span": [35, 39]
      },
      {
        "subject": "C1156Y",
        "object": "crizotinib",
        "sbj_char_span": [59, 65],
        "obj_char_span": [148, 158],
        "rel_type": "resistance",
        "sbj_tok_span": [12, 16],
        "obj_tok_span": [35, 39]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Taken together , these findings indicated that the Met inhibitor crizotinib plus a new generation EGFR-TKI , either afatinib or WZ4002 , circumvented resistance to HGF in an autocrine manner , in the presence or absence of the EGFR T790M mutation or Met gene amplification .",
    "entity_list": [
      {
        "name": "afatinib",
        "ent_type": "drug",
        "char_span": [116, 124],
        "tok_span": [24, 26]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [232, 237],
        "tok_span": [53, 57]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "afatinib",
        "sbj_char_span": [232, 237],
        "obj_char_span": [116, 124],
        "rel_type": "response",
        "sbj_tok_span": [53, 57],
        "obj_tok_span": [24, 26]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "In both in vitro and in vivo preclinical models , afatinib demonstrated increased affinity to common EGFR mutations , as well as the T790M mutation .",
    "entity_list": [
      {
        "name": "afatinib",
        "ent_type": "drug",
        "char_span": [50, 58],
        "tok_span": [10, 12]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [133, 138],
        "tok_span": [24, 28]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "afatinib",
        "sbj_char_span": [133, 138],
        "obj_char_span": [50, 58],
        "rel_type": "response",
        "sbj_tok_span": [24, 28],
        "obj_tok_span": [10, 12]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Ph II ; randomized , single-arm n = 129 ; Taiwanese and US ; chemo-naïve , or one previous line of chemotherapy ; exon 19 deletion ( n = 52 ) ; L858R ( n = 54 ) ; other ( n = 23 ) Afatinib 40 mg or 50 mg/day PFS : 14 months",
    "entity_list": [
      {
        "name": "; L858R",
        "ent_type": "variant",
        "char_span": [142, 149],
        "tok_span": [36, 41]
      },
      {
        "name": ") Afatinib",
        "ent_type": "drug",
        "char_span": [178, 188],
        "tok_span": [52, 55]
      }
    ],
    "relation_list": [
      {
        "subject": "; L858R",
        "object": ") Afatinib",
        "sbj_char_span": [142, 149],
        "obj_char_span": [178, 188],
        "rel_type": "sensitivity",
        "sbj_tok_span": [36, 41],
        "obj_tok_span": [52, 55]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Second generation EGFR-TKIs , such as BIBW2992 ( afatinib ) and PF00299804 ( dacomitinib ) , have been recommended in order to overcome the T790M mediated resistance considering that these potent , irreversible EGFR-TKIs no longer compete with ATP once they have become covalently bound to the kinase domain , .",
    "entity_list": [
      {
        "name": "afatinib",
        "ent_type": "drug",
        "char_span": [49, 57],
        "tok_span": [14, 16]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [140, 145],
        "tok_span": [38, 42]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "afatinib",
        "sbj_char_span": [140, 145],
        "obj_char_span": [49, 57],
        "rel_type": "response",
        "sbj_tok_span": [38, 42],
        "obj_tok_span": [14, 16]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Two phase III trials compared afatinib to a platinum-doublet in patients with advanced EGFR mutant NSCLC , and a combined analysis for overall survival was presented at ASCO , as well as subset analyses based on EGFR mutation subtype ( exon 19 deletion and exon 21 L858R point mutation ) . ",
    "entity_list": [
      {
        "name": "afatinib",
        "ent_type": "drug",
        "char_span": [30, 38],
        "tok_span": [5, 7]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [265, 270],
        "tok_span": [51, 55]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "afatinib",
        "sbj_char_span": [265, 270],
        "obj_char_span": [30, 38],
        "rel_type": "sensitivity",
        "sbj_tok_span": [51, 55],
        "obj_tok_span": [5, 7]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Thus , an alternate schedule of drug administration , such as intermittent or pulse high-dose therapy using afatinib to determine its activity against T790M ( NCT01647711 ) , is under investigation .",
    "entity_list": [
      {
        "name": "afatinib",
        "ent_type": "drug",
        "char_span": [108, 116],
        "tok_span": [19, 21]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [151, 156],
        "tok_span": [26, 30]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "afatinib",
        "sbj_char_span": [151, 156],
        "obj_char_span": [108, 116],
        "rel_type": "response",
        "sbj_tok_span": [26, 30],
        "obj_tok_span": [19, 21]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Ponatinib ( AP24534 ) is a multitargeted BCR-ABL/SRC kinase inhibitor with potent in vitro activity against all tested mutants of BCR-ABL including T315I , and clinical activity has been reported in patients with a T315I mutation .",
    "entity_list": [
      {
        "name": "Ponatinib",
        "ent_type": "drug",
        "char_span": [0, 9],
        "tok_span": [0, 2]
      },
      {
        "name": "T315I",
        "ent_type": "variant",
        "char_span": [148, 153],
        "tok_span": [36, 40]
      },
      {
        "name": "AP24534",
        "ent_type": "drug",
        "char_span": [12, 19],
        "tok_span": [3, 7]
      }
    ],
    "relation_list": [
      {
        "subject": "T315I",
        "object": "Ponatinib",
        "sbj_char_span": [148, 153],
        "obj_char_span": [0, 9],
        "rel_type": "response",
        "sbj_tok_span": [36, 40],
        "obj_tok_span": [0, 2]
      },
      {
        "subject": "T315I",
        "object": "AP24534",
        "sbj_char_span": [148, 153],
        "obj_char_span": [12, 19],
        "rel_type": "response",
        "sbj_tok_span": [36, 40],
        "obj_tok_span": [3, 7]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Ponatinib is a multi targeted TKI with strong activity against BCR–ABL and imatinib-resistant mutants including , for the first time , T315I .",
    "entity_list": [
      {
        "name": "Ponatinib",
        "ent_type": "drug",
        "char_span": [0, 9],
        "tok_span": [0, 2]
      },
      {
        "name": ", T315I",
        "ent_type": "variant",
        "char_span": [133, 140],
        "tok_span": [28, 33]
      }
    ],
    "relation_list": [
      {
        "subject": ", T315I",
        "object": "Ponatinib",
        "sbj_char_span": [133, 140],
        "obj_char_span": [0, 9],
        "rel_type": "response",
        "sbj_tok_span": [28, 33],
        "obj_tok_span": [0, 2]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "For instance , T315I is a unique mutation making the CML patient irresponsive to most TKIs ( excluding ponatinib ) and leads allografting to become an option in the case .",
    "entity_list": [
      {
        "name": "ponatinib",
        "ent_type": "drug",
        "char_span": [103, 112],
        "tok_span": [25, 29]
      },
      {
        "name": "T315I",
        "ent_type": "variant",
        "char_span": [15, 20],
        "tok_span": [3, 7]
      }
    ],
    "relation_list": [
      {
        "subject": "T315I",
        "object": "ponatinib",
        "sbj_char_span": [15, 20],
        "obj_char_span": [103, 112],
        "rel_type": "response",
        "sbj_tok_span": [3, 7],
        "obj_tok_span": [25, 29]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "AP-24534 and XL-228 have demonstrated activity in cell culture and in mice bearing xenograft tumors expressing T315I BCR-ABL mutants .",
    "entity_list": [
      {
        "name": "AP-24534",
        "ent_type": "drug",
        "char_span": [0, 8],
        "tok_span": [0, 4]
      },
      {
        "name": "T315I",
        "ent_type": "variant",
        "char_span": [111, 116],
        "tok_span": [22, 26]
      }
    ],
    "relation_list": [
      {
        "subject": "T315I",
        "object": "AP-24534",
        "sbj_char_span": [111, 116],
        "obj_char_span": [0, 8],
        "rel_type": "response",
        "sbj_tok_span": [22, 26],
        "obj_tok_span": [0, 4]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "These agents are irreversible inhibitors and covalently bind to Cys-797 of the EGFR ATP binding domain , and they seem to overcome resistance introduced by the T790M mutation that is seen with gefitinib and erlotinib .",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [207, 216],
        "tok_span": [44, 48]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [160, 165],
        "tok_span": [30, 34]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "erlotinib",
        "sbj_char_span": [160, 165],
        "obj_char_span": [207, 216],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [30, 34],
        "obj_tok_span": [44, 48]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Patients with either the exon 19 deletion or the L858R mutation received erlotinib , while those with wild-type EGFR received chemotherapy based on BRCA1 levels : those with low levels received cisplatin plus gemcitabine ;",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [73, 82],
        "tok_span": [15, 19]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [49, 54],
        "tok_span": [9, 13]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "erlotinib",
        "sbj_char_span": [49, 54],
        "obj_char_span": [73, 82],
        "rel_type": "sensitivity",
        "sbj_tok_span": [9, 13],
        "obj_tok_span": [15, 19]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Therapy of NSCLC with first generation small molecule EGFR kinase inhibitors , gefitinib and erlotinib , is severely limited by two main factors : first , the poor sensitivity to TKIs of tumor cells expressing wild type forms of the receptor ; second the emergence of drug resistance in virtually all tumors bearing EGFR mutations initially sensitive for the presence of either exon 19 deletions or exon 21 mutation L858R .",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [93, 102],
        "tok_span": [17, 21]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [416, 421],
        "tok_span": [76, 80]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "erlotinib",
        "sbj_char_span": [416, 421],
        "obj_char_span": [93, 102],
        "rel_type": "sensitivity",
        "sbj_tok_span": [76, 80],
        "obj_tok_span": [17, 21]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "For example , the T790M mutation of the EGFR gene retains the ability of the receptor to activate the downstream pathway but simultaneously decreases binding of gefitinib and erlotinib to the receptor and thus leads to drug resistance .",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [175, 184],
        "tok_span": [34, 38]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [18, 23],
        "tok_span": [4, 8]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "erlotinib",
        "sbj_char_span": [18, 23],
        "obj_char_span": [175, 184],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [4, 8],
        "obj_tok_span": [34, 38]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "( A ) L755 packs against helix C , closest to residues Ala763 and Ile767 , and makes no contacts with the inhibitors ( structure 1M17 with inhibitor erlotinib is depicted lower left ) . ( B ) Comparing the active structure of 1M17 ( green ) to an inactive representative 1XKK bound to lapatinib shows the loss of L755 interactions ( cyan ) . ( C ) Overlay of AEE788 bound structures of EGFR ( 2J6M , active , blue ) and EGFR T790M ( 2JIU , inactive , yellow ) .",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [149, 158],
        "tok_span": [38, 42]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [425, 430],
        "tok_span": [112, 116]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "erlotinib",
        "sbj_char_span": [425, 430],
        "obj_char_span": [149, 158],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [112, 116],
        "obj_tok_span": [38, 42]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "As expected , only ponatinib caused cell death on 86 % of T315I mutated BCR-ABL1 expressing cells ( UT-7-315 ) . ",
    "entity_list": [
      {
        "name": "ponatinib",
        "ent_type": "drug",
        "char_span": [19, 28],
        "tok_span": [4, 8]
      },
      {
        "name": "T315I",
        "ent_type": "variant",
        "char_span": [58, 63],
        "tok_span": [15, 19]
      }
    ],
    "relation_list": [
      {
        "subject": "T315I",
        "object": "ponatinib",
        "sbj_char_span": [58, 63],
        "obj_char_span": [19, 28],
        "rel_type": "response",
        "sbj_tok_span": [15, 19],
        "obj_tok_span": [4, 8]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "In the absence of MS-5 niche , compound mutations appeared to be the major way to escape ponatinib therapy , especially via the occurrence of p-loop mutations in addition to T315I .",
    "entity_list": [
      {
        "name": "ponatinib",
        "ent_type": "drug",
        "char_span": [89, 98],
        "tok_span": [19, 23]
      },
      {
        "name": "T315I",
        "ent_type": "variant",
        "char_span": [174, 179],
        "tok_span": [37, 41]
      }
    ],
    "relation_list": [
      {
        "subject": "T315I",
        "object": "ponatinib",
        "sbj_char_span": [174, 179],
        "obj_char_span": [89, 98],
        "rel_type": "response",
        "sbj_tok_span": [37, 41],
        "obj_tok_span": [19, 23]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "However , the therapeutic efficacy of gefitinib increases noticeably in patients with lung cancer who have somatic mutations in the EGFR TK domain such as deletions in exon 19 or a point mutation ( L858R ) in exon 21 .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [38, 47],
        "tok_span": [6, 10]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [198, 203],
        "tok_span": [38, 42]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "gefitinib",
        "sbj_char_span": [198, 203],
        "obj_char_span": [38, 47],
        "rel_type": "sensitivity",
        "sbj_tok_span": [38, 42],
        "obj_tok_span": [6, 10]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "H358 and H441 cells expressing WT EGFR or H1975 cells expressing L858R and T790M mutant EGFR were left untreated ( NT ) or treated for 24 h with gefitinib ( 10 , 2 , 0.4 , 0.08 μM ) or DMSO ( D ) .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [145, 154],
        "tok_span": [40, 44]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [75, 80],
        "tok_span": [22, 26]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [65, 70],
        "tok_span": [17, 21]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "gefitinib",
        "sbj_char_span": [75, 80],
        "obj_char_span": [145, 154],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [22, 26],
        "obj_tok_span": [40, 44]
      },
      {
        "subject": "L858R",
        "object": "gefitinib",
        "sbj_char_span": [65, 70],
        "obj_char_span": [145, 154],
        "rel_type": "sensitivity",
        "sbj_tok_span": [17, 21],
        "obj_tok_span": [40, 44]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "We tested this hypothesis in gefitinib-sensitive HCC827 stable cell lines expressing activating deletion mutant L747-S752 ( HCC/Del ) EGFR or in the gefitinib-resistant lines HCC827-delL747-S752-T790M ( HCC/Del-TM ) , harboring both the delL747-S752 and T790M mutations , as well as the H1975 cell line harboring L858R-T790M double mutations .",
    "entity_list": [
      {
        "name": "gefitinib-sensitive",
        "ent_type": "drug",
        "char_span": [29, 48],
        "tok_span": [5, 11]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [254, 259],
        "tok_span": [81, 85]
      },
      {
        "name": "gefitinib-resistant",
        "ent_type": "drug",
        "char_span": [149, 168],
        "tok_span": [37, 43]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "gefitinib-sensitive",
        "sbj_char_span": [254, 259],
        "obj_char_span": [29, 48],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [81, 85],
        "obj_tok_span": [5, 11]
      },
      {
        "subject": "T790M",
        "object": "gefitinib-resistant",
        "sbj_char_span": [254, 259],
        "obj_char_span": [149, 168],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [81, 85],
        "obj_tok_span": [37, 43]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "The increase in BIM expression and apoptosis are inhibited by the secondary resistant mutation , T790M . ( A ) Modulation of signaling following gefitinib treatment in HCC827 cells expressing EGFR mutants .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [145, 154],
        "tok_span": [29, 33]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [97, 102],
        "tok_span": [16, 20]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "gefitinib",
        "sbj_char_span": [97, 102],
        "obj_char_span": [145, 154],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [16, 20],
        "obj_tok_span": [29, 33]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "The Secondary Resistant Mutations L747S and T790M Affect Gefitinib Induced Apoptosis and Inhibit BIM Up-Regulation ( A ) Top : Annexin V apoptosis assay : Ba/F3 cells expressing L858R (LR) , L858R-L747S # 4 ( LR-LS ) , or L858R-T790M (LR-TM) cells were grown in the absence or presence of gefitinib for 24 h .",
    "entity_list": [
      {
        "name": "Gefitinib",
        "ent_type": "drug",
        "char_span": [57, 66],
        "tok_span": [16, 19]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [44, 49],
        "tok_span": [10, 14]
      },
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [289, 298],
        "tok_span": [96, 100]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [178, 183],
        "tok_span": [47, 51]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "Gefitinib",
        "sbj_char_span": [44, 49],
        "obj_char_span": [57, 66],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [10, 14],
        "obj_tok_span": [16, 19]
      },
      {
        "subject": "T790M",
        "object": "gefitinib",
        "sbj_char_span": [44, 49],
        "obj_char_span": [289, 298],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [10, 14],
        "obj_tok_span": [96, 100]
      },
      {
        "subject": "L858R",
        "object": "Gefitinib",
        "sbj_char_span": [178, 183],
        "obj_char_span": [57, 66],
        "rel_type": "sensitivity",
        "sbj_tok_span": [47, 51],
        "obj_tok_span": [16, 19]
      },
      {
        "subject": "L858R",
        "object": "gefitinib",
        "sbj_char_span": [178, 183],
        "obj_char_span": [289, 298],
        "rel_type": "sensitivity",
        "sbj_tok_span": [47, 51],
        "obj_tok_span": [96, 100]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "H3255 carries the L858R EGFR exon 21 point mutation and has an IC50 of 0.015 μM to gefitinib .",
    "entity_list": [
      {
        "name": "to gefitinib",
        "ent_type": "drug",
        "char_span": [80, 92],
        "tok_span": [26, 31]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [18, 23],
        "tok_span": [5, 9]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "to gefitinib",
        "sbj_char_span": [18, 23],
        "obj_char_span": [80, 92],
        "rel_type": "sensitivity",
        "sbj_tok_span": [5, 9],
        "obj_tok_span": [26, 31]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Ba/F3 cells expressing L858R (LR) , L858R-L747S # 4 ( LR-LS ) , or L858R-T790M (LR-TM) were plated in 24-well plates at a density of 1 × 105/well and treated with 0.1 % DMSO ( control ) or gefitinib for 24 h .",
    "entity_list": [
      {
        "name": "or gefitinib",
        "ent_type": "drug",
        "char_span": [186, 198],
        "tok_span": [73, 78]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [23, 28],
        "tok_span": [6, 10]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "or gefitinib",
        "sbj_char_span": [23, 28],
        "obj_char_span": [186, 198],
        "rel_type": "sensitivity",
        "sbj_tok_span": [6, 10],
        "obj_tok_span": [73, 78]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Transient transfection experiments utilizing COS-7 cells demonstrated that auto-phosphorylation of the original L858R EGFR was inhibited by lower concentrations of gefitinib or erlotinib than the L858R-L747S or L858R-T790M constructs ( A ) . ",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [164, 173],
        "tok_span": [28, 32]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [112, 117],
        "tok_span": [17, 21]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "gefitinib",
        "sbj_char_span": [112, 117],
        "obj_char_span": [164, 173],
        "rel_type": "sensitivity",
        "sbj_tok_span": [17, 21],
        "obj_tok_span": [28, 32]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "A sixfold or 14-fold higher concentration of gefitinib was required to inhibit the growth of cells expressing G719X or L861Q , respectively , compared with cells expressing L858R .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [45, 54],
        "tok_span": [10, 14]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [173, 178],
        "tok_span": [39, 43]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "gefitinib",
        "sbj_char_span": [173, 178],
        "obj_char_span": [45, 54],
        "rel_type": "sensitivity",
        "sbj_tok_span": [39, 43],
        "obj_tok_span": [10, 14]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "( A ) The T790M secondary mutation in exon 20 of EGFR is present in 50 % –70 % of NSCLC patients who acquire resistance to EGFR-TKIs , such as gefitinib or erlotinib .",
    "entity_list": [
      {
        "name": "as gefitinib",
        "ent_type": "drug",
        "char_span": [140, 152],
        "tok_span": [36, 41]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [10, 15],
        "tok_span": [4, 8]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "as gefitinib",
        "sbj_char_span": [10, 15],
        "obj_char_span": [140, 152],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [4, 8],
        "obj_tok_span": [36, 41]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Second-generation irreversible EGFR inhibitors , which bind irreversibly in the ATP binding pocket of EGFR through a covalent bond at C797 , were shown to be more potent inhibitors of the second-site T790M mutation than erlotinib or gefitinib in pre-clinical models ( ) .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [233, 242],
        "tok_span": [50, 54]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [200, 205],
        "tok_span": [39, 43]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "gefitinib",
        "sbj_char_span": [200, 205],
        "obj_char_span": [233, 242],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [39, 43],
        "obj_tok_span": [50, 54]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "These patients respond to gefitinib , but after a period of time , their tumors develop a T790M exon 20 mutation .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [26, 35],
        "tok_span": [4, 8]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [90, 95],
        "tok_span": [20, 24]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "gefitinib",
        "sbj_char_span": [90, 95],
        "obj_char_span": [26, 35],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [20, 24],
        "obj_tok_span": [4, 8]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "The T790M mutation could also initially combine with erlotinib or gefitinib in the body and also contribute to initial drug resistance .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [66, 75],
        "tok_span": [16, 20]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [4, 9],
        "tok_span": [1, 5]
      },
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [53, 62],
        "tok_span": [11, 15]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "gefitinib",
        "sbj_char_span": [4, 9],
        "obj_char_span": [66, 75],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [1, 5],
        "obj_tok_span": [16, 20]
      },
      {
        "subject": "T790M",
        "object": "erlotinib",
        "sbj_char_span": [4, 9],
        "obj_char_span": [53, 62],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [1, 5],
        "obj_tok_span": [11, 15]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Sensitive detection methods have identified a proportion of tyrosin- kinase- naive tumors that carry T790M , a resistant tumor cell clones that may be selected during the exposure to gefitinib or erlotinib .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [183, 192],
        "tok_span": [37, 41]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [101, 106],
        "tok_span": [19, 23]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "gefitinib",
        "sbj_char_span": [101, 106],
        "obj_char_span": [183, 192],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [19, 23],
        "obj_tok_span": [37, 41]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "T790M ) in four EGFR doublets have been reported after treatment with gefitinib and erlotinib and associated with drug resistance and disease relapse , .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [70, 79],
        "tok_span": [16, 20]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [0, 5],
        "tok_span": [0, 4]
      },
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [84, 93],
        "tok_span": [21, 25]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "gefitinib",
        "sbj_char_span": [0, 5],
        "obj_char_span": [70, 79],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [0, 4],
        "obj_tok_span": [16, 20]
      },
      {
        "subject": "T790M",
        "object": "erlotinib",
        "sbj_char_span": [0, 5],
        "obj_char_span": [84, 93],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [0, 4],
        "obj_tok_span": [21, 25]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "In contrast , the secondary EGFR mutation T790M causes insensitivity to gefitinib and is detectable in 50 % of patients after the acquisition of drug resistance ( ) .",
    "entity_list": [
      {
        "name": "gefitinib",
        "ent_type": "drug",
        "char_span": [72, 81],
        "tok_span": [15, 19]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [42, 47],
        "tok_span": [7, 11]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "gefitinib",
        "sbj_char_span": [42, 47],
        "obj_char_span": [72, 81],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [7, 11],
        "obj_tok_span": [15, 19]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "OPTIMAL People’s Republic of China Erlotinib ( 82 ) versus CBDCA plus GEM ( 72 ) Exon 19 deletion or L858R",
    "entity_list": [
      {
        "name": "China Erlotinib",
        "ent_type": "drug",
        "char_span": [29, 44],
        "tok_span": [8, 12]
      },
      {
        "name": "or L858R",
        "ent_type": "variant",
        "char_span": [98, 106],
        "tok_span": [29, 34]
      }
    ],
    "relation_list": [
      {
        "subject": "or L858R",
        "object": "China Erlotinib",
        "sbj_char_span": [98, 106],
        "obj_char_span": [29, 44],
        "rel_type": "sensitivity",
        "sbj_tok_span": [29, 34],
        "obj_tok_span": [8, 12]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "ENSURE People’s Republic of China Erlotinib ( 110 ) versus CDDP plus GEM ( 107 ) Exon 19 deletion or L858R 63 versus 34",
    "entity_list": [
      {
        "name": "China Erlotinib",
        "ent_type": "drug",
        "char_span": [28, 43],
        "tok_span": [7, 11]
      },
      {
        "name": "or L858R",
        "ent_type": "variant",
        "char_span": [98, 106],
        "tok_span": [27, 32]
      }
    ],
    "relation_list": [
      {
        "subject": "or L858R",
        "object": "China Erlotinib",
        "sbj_char_span": [98, 106],
        "obj_char_span": [28, 43],
        "rel_type": "sensitivity",
        "sbj_tok_span": [27, 32],
        "obj_tok_span": [7, 11]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "The H1975 cell ( L858R + T790 M ) and the EGFR wild-type cells ( H157 , H460 and A549 ) were resistant to erlotinib , with IC50 values of 9.07 ± 2.11 , 20.73 ± 4.66 , 4.58 ± 2.08 , and 7.27 ± 0.69 µmol/L , respectively ( Fig. b ) .",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [106, 115],
        "tok_span": [37, 41]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [17, 22],
        "tok_span": [6, 10]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "erlotinib",
        "sbj_char_span": [17, 22],
        "obj_char_span": [106, 115],
        "rel_type": "sensitivity",
        "sbj_tok_span": [6, 10],
        "obj_tok_span": [37, 41]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "For example , patients with epidermal growth factor receptor (EGFR) mutations , most frequently exon 19 deletions and exon 21 point mutation L858R may respond to EGFR–TKI , like gefitinib or erlotinib .",
    "entity_list": [
      {
        "name": "or erlotinib",
        "ent_type": "drug",
        "char_span": [188, 200],
        "tok_span": [41, 46]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [141, 146],
        "tok_span": [24, 28]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "or erlotinib",
        "sbj_char_span": [141, 146],
        "obj_char_span": [188, 200],
        "rel_type": "sensitivity",
        "sbj_tok_span": [24, 28],
        "obj_tok_span": [41, 46]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Another seven studies ( clinical trials or retrospective studies ) , , , , , , involving 549 advanced NSCLC patients receiving first-line EGFR-TKIs ( gefitinib or erlotinib ) presented direct comparison of exon 19 deletion and L858R mutation for PFS .",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [163, 172],
        "tok_span": [36, 40]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [227, 232],
        "tok_span": [49, 53]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "erlotinib",
        "sbj_char_span": [227, 232],
        "obj_char_span": [163, 172],
        "rel_type": "sensitivity",
        "sbj_tok_span": [49, 53],
        "obj_tok_span": [36, 40]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "However , treatment with gefitinib and erlotinib will eventually fail because of the development of acquired drug resistance resulting from amplification of the MET proto-oncogene or the threonine-to-methionine amino acid substitution at position 790 ( T790M ) of EGFR , which is detected in 50 % of clinically resistant patients , .",
    "entity_list": [
      {
        "name": "erlotinib",
        "ent_type": "drug",
        "char_span": [39, 48],
        "tok_span": [9, 13]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [253, 258],
        "tok_span": [50, 54]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "erlotinib",
        "sbj_char_span": [253, 258],
        "obj_char_span": [39, 48],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [50, 54],
        "obj_tok_span": [9, 13]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Similar mutations in the homologous residues of the kinase domains of PDGFRA ( T674I ) and KIT ( T670I ) account for imatinib resistance in some patients with hypereosinophilic syndrome and gastrointestinal stromal cell tumors , respectively .",
    "entity_list": [
      {
        "name": "imatinib",
        "ent_type": "drug",
        "char_span": [117, 125],
        "tok_span": [30, 32]
      },
      {
        "name": "T674I",
        "ent_type": "variant",
        "char_span": [79, 84],
        "tok_span": [14, 18]
      },
      {
        "name": "T670I",
        "ent_type": "variant",
        "char_span": [97, 102],
        "tok_span": [23, 27]
      }
    ],
    "relation_list": [
      {
        "subject": "T674I",
        "object": "imatinib",
        "sbj_char_span": [79, 84],
        "obj_char_span": [117, 125],
        "rel_type": "resistance",
        "sbj_tok_span": [14, 18],
        "obj_tok_span": [30, 32]
      },
      {
        "subject": "T670I",
        "object": "imatinib",
        "sbj_char_span": [97, 102],
        "obj_char_span": [117, 125],
        "rel_type": "resistance",
        "sbj_tok_span": [23, 27],
        "obj_tok_span": [30, 32]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Similar to mutations in BCR-ABL ( T315I ) or in KIT ( T670I ) that underlie resistance to imatinib , T790M is thought to interfere with the binding of EGFR-TKIs at the adenosine triphosphate binding cleft of EGFR . , , On the other hand , the affinity of this cleft for adenosine triphosphate is increased by T790M .",
    "entity_list": [
      {
        "name": "imatinib",
        "ent_type": "drug",
        "char_span": [90, 98],
        "tok_span": [28, 30]
      },
      {
        "name": "T670I",
        "ent_type": "variant",
        "char_span": [54, 59],
        "tok_span": [19, 23]
      }
    ],
    "relation_list": [
      {
        "subject": "T670I",
        "object": "imatinib",
        "sbj_char_span": [54, 59],
        "obj_char_span": [90, 98],
        "rel_type": "resistance",
        "sbj_tok_span": [19, 23],
        "obj_tok_span": [28, 30]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Moreover , the D842V PDGFRA mutation , classically resistant to imatinib , confers also a sunitinib resistance in vitro .",
    "entity_list": [
      {
        "name": "imatinib",
        "ent_type": "drug",
        "char_span": [64, 72],
        "tok_span": [15, 17]
      },
      {
        "name": "D842V",
        "ent_type": "variant",
        "char_span": [15, 20],
        "tok_span": [3, 7]
      }
    ],
    "relation_list": [
      {
        "subject": "D842V",
        "object": "imatinib",
        "sbj_char_span": [15, 20],
        "obj_char_span": [64, 72],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [3, 7],
        "obj_tok_span": [15, 17]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Activating mutations Frequency at diagnosis , Predictive value for imatinib Secondary mutations of imatinib resistance , – Predictive value for sunitinib KIT Exon 9 10 % 70 % –75 % 58 % Exon 11 67 % 90 % –95 % 34 % Exon 13 1 % ± Yes + Exon 14 0 % Yes + Exon 17 1 % ± Yes − Exon 18 0 % Yes − PDGFRA 33 % –60 % Exon 12 1 % + Exon 14 & lt ; 1 % + Exon 18 5 % ± excepted for D842V Yes − for D842V",
    "entity_list": [
      {
        "name": "imatinib",
        "ent_type": "drug",
        "char_span": [67, 75],
        "tok_span": [11, 13]
      },
      {
        "name": "for D842V",
        "ent_type": "variant",
        "char_span": [367, 376],
        "tok_span": [114, 119]
      },
      {
        "name": "imatinib",
        "ent_type": "drug",
        "char_span": [99, 107],
        "tok_span": [16, 18]
      }
    ],
    "relation_list": [
      {
        "subject": "for D842V",
        "object": "imatinib",
        "sbj_char_span": [367, 376],
        "obj_char_span": [67, 75],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [114, 119],
        "obj_tok_span": [11, 13]
      },
      {
        "subject": "for D842V",
        "object": "imatinib",
        "sbj_char_span": [367, 376],
        "obj_char_span": [99, 107],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [114, 119],
        "obj_tok_span": [16, 18]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "PDGFRA mutation T674I confers imatinib resistance .",
    "entity_list": [
      {
        "name": "imatinib",
        "ent_type": "drug",
        "char_span": [30, 38],
        "tok_span": [8, 10]
      },
      {
        "name": "T674I",
        "ent_type": "variant",
        "char_span": [16, 21],
        "tok_span": [3, 7]
      }
    ],
    "relation_list": [
      {
        "subject": "T674I",
        "object": "imatinib",
        "sbj_char_span": [16, 21],
        "obj_char_span": [30, 38],
        "rel_type": "resistance",
        "sbj_tok_span": [3, 7],
        "obj_tok_span": [8, 10]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "A separate mutation , F1174L , has been described in a patient with an inflammatory myofibroblastic tumor and RANPB2-ALK translocation who progressed on crizotinib .",
    "entity_list": [
      {
        "name": "crizotinib",
        "ent_type": "drug",
        "char_span": [153, 163],
        "tok_span": [34, 38]
      },
      {
        "name": "F1174L",
        "ent_type": "variant",
        "char_span": [22, 28],
        "tok_span": [4, 8]
      }
    ],
    "relation_list": [
      {
        "subject": "F1174L",
        "object": "crizotinib",
        "sbj_char_span": [22, 28],
        "obj_char_span": [153, 163],
        "rel_type": "resistance",
        "sbj_tok_span": [4, 8],
        "obj_tok_span": [34, 38]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "A pooled analysis showed that afatinib significantly improved OS in patients with advanced NSCLC harboring common EGFR mutations ( Del 19 and L858R ) when compared with standard chemotherapy in the first-line setting .",
    "entity_list": [
      {
        "name": "afatinib",
        "ent_type": "drug",
        "char_span": [30, 38],
        "tok_span": [5, 7]
      },
      {
        "name": "L858R",
        "ent_type": "variant",
        "char_span": [142, 147],
        "tok_span": [23, 27]
      }
    ],
    "relation_list": [
      {
        "subject": "L858R",
        "object": "afatinib",
        "sbj_char_span": [142, 147],
        "obj_char_span": [30, 38],
        "rel_type": "sensitivity",
        "sbj_tok_span": [23, 27],
        "obj_tok_span": [5, 7]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "It is noteworthy that in H1975 cells carrying the T790M resistance mutation , afatinib had a slightly higher activity than the reversible kinase inhibitors , but this difference was small and the activity was still logarithmically inferior to what was observed in the HCC827 cell lines .",
    "entity_list": [
      {
        "name": "afatinib",
        "ent_type": "drug",
        "char_span": [78, 86],
        "tok_span": [18, 20]
      },
      {
        "name": "T790M",
        "ent_type": "variant",
        "char_span": [50, 55],
        "tok_span": [11, 15]
      }
    ],
    "relation_list": [
      {
        "subject": "T790M",
        "object": "afatinib",
        "sbj_char_span": [50, 55],
        "obj_char_span": [78, 86],
        "rel_type": "response",
        "sbj_tok_span": [11, 15],
        "obj_tok_span": [18, 20]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "In a recent report , the c-KIT mutation L576P was associated with resistance to multiple KIT inhibitors including imatinib , nilotinib , and sorafenib , but objective tumor responses could be induced in 2 patients bearing the KIT L576P mutation after treatment with dasatinib .",
    "entity_list": [
      {
        "name": "dasatinib",
        "ent_type": "drug",
        "char_span": [266, 275],
        "tok_span": [58, 60]
      },
      {
        "name": "L576P",
        "ent_type": "variant",
        "char_span": [40, 45],
        "tok_span": [11, 15]
      }
    ],
    "relation_list": [
      {
        "subject": "L576P",
        "object": "dasatinib",
        "sbj_char_span": [40, 45],
        "obj_char_span": [266, 275],
        "rel_type": "sensitivity",
        "sbj_tok_span": [11, 15],
        "obj_tok_span": [58, 60]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "The T315I mutation experiences increased ( −4.11 kcal/mol ) and T315A mutation experiences decreased electrostatic interactions ( −2.05 kcal/mol ) , and the mutation G250E contributes increased electrostatic interaction ( −0.32 kcal/mol ) while binding to ponatinib .",
    "entity_list": [
      {
        "name": "to ponatinib",
        "ent_type": "drug",
        "char_span": [253, 265],
        "tok_span": [55, 60]
      },
      {
        "name": "T315I",
        "ent_type": "variant",
        "char_span": [4, 9],
        "tok_span": [1, 5]
      }
    ],
    "relation_list": [
      {
        "subject": "T315I",
        "object": "to ponatinib",
        "sbj_char_span": [4, 9],
        "obj_char_span": [253, 265],
        "rel_type": "response",
        "sbj_tok_span": [1, 5],
        "obj_tok_span": [55, 60]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "The Phe359 caps ponatinib binding site close to the activation loop and undergoes conformational changes with most mutations in particular , the P-loop residues ( G250E and Y253H ) and the gatekeeper mutation T315I on the β5- strand .",
    "entity_list": [
      {
        "name": "ponatinib",
        "ent_type": "drug",
        "char_span": [16, 25],
        "tok_span": [5, 9]
      },
      {
        "name": "T315I",
        "ent_type": "variant",
        "char_span": [209, 214],
        "tok_span": [47, 51]
      }
    ],
    "relation_list": [
      {
        "subject": "T315I",
        "object": "ponatinib",
        "sbj_char_span": [209, 214],
        "obj_char_span": [16, 25],
        "rel_type": "response",
        "sbj_tok_span": [47, 51],
        "obj_tok_span": [5, 9]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "The high-affinity dual inhibitors for wt and T315I ABL1 kinase domains can be divided roughly into two major scaffold categories : ponatinib-like and non-ponatinib inhibitors .",
    "entity_list": [
      {
        "name": "ponatinib-like",
        "ent_type": "drug",
        "char_span": [131, 145],
        "tok_span": [28, 34]
      },
      {
        "name": "T315I",
        "ent_type": "variant",
        "char_span": [45, 50],
        "tok_span": [9, 13]
      },
      {
        "name": "non-ponatinib",
        "ent_type": "drug",
        "char_span": [150, 163],
        "tok_span": [35, 41]
      }
    ],
    "relation_list": [
      {
        "subject": "T315I",
        "object": "ponatinib-like",
        "sbj_char_span": [45, 50],
        "obj_char_span": [131, 145],
        "rel_type": "response",
        "sbj_tok_span": [9, 13],
        "obj_tok_span": [28, 34]
      },
      {
        "subject": "T315I",
        "object": "non-ponatinib",
        "sbj_char_span": [45, 50],
        "obj_char_span": [150, 163],
        "rel_type": "response",
        "sbj_tok_span": [9, 13],
        "obj_tok_span": [35, 41]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Thus , the ponatinib scaffold provides the greatest binding energy components via predominantly polar interactions , especially H-bonding at the hinge , but variations in the side chains and their mostly hydrophobic interactions cause the variations in binding affinity seen mostly for binding to the T315I isoform .",
    "entity_list": [
      {
        "name": "ponatinib",
        "ent_type": "drug",
        "char_span": [11, 20],
        "tok_span": [3, 7]
      },
      {
        "name": "T315I",
        "ent_type": "variant",
        "char_span": [301, 306],
        "tok_span": [51, 55]
      }
    ],
    "relation_list": [
      {
        "subject": "T315I",
        "object": "ponatinib",
        "sbj_char_span": [301, 306],
        "obj_char_span": [11, 20],
        "rel_type": "response",
        "sbj_tok_span": [51, 55],
        "obj_tok_span": [3, 7]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Moroever , while a recently approved TKI , Ponatinib , is effective in patients with T315I mutation , cardiovascular , cerebrovascular and peripheral vascular thrombosis , including fatal myocardial infarction and stroke , have occurred in ponatinib treated patients .",
    "entity_list": [
      {
        "name": "Ponatinib",
        "ent_type": "drug",
        "char_span": [43, 52],
        "tok_span": [11, 13]
      },
      {
        "name": "T315I",
        "ent_type": "variant",
        "char_span": [85, 90],
        "tok_span": [19, 23]
      },
      {
        "name": "ponatinib",
        "ent_type": "drug",
        "char_span": [240, 249],
        "tok_span": [43, 47]
      }
    ],
    "relation_list": [
      {
        "subject": "T315I",
        "object": "Ponatinib",
        "sbj_char_span": [85, 90],
        "obj_char_span": [43, 52],
        "rel_type": "response",
        "sbj_tok_span": [19, 23],
        "obj_tok_span": [11, 13]
      },
      {
        "subject": "T315I",
        "object": "ponatinib",
        "sbj_char_span": [85, 90],
        "obj_char_span": [240, 249],
        "rel_type": "response",
        "sbj_tok_span": [19, 23],
        "obj_tok_span": [43, 47]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Preliminary results from an ongoing phase 1 dose-escalation study of the multikinase , pan–BCR-ABL inhibitor ponatinib ( AP24534 ) showed antileukemic activity in patients with refractory CML , including patients with the T315I mutation .",
    "entity_list": [
      {
        "name": "inhibitor ponatinib",
        "ent_type": "drug",
        "char_span": [99, 118],
        "tok_span": [23, 28]
      },
      {
        "name": "the T315I",
        "ent_type": "variant",
        "char_span": [218, 227],
        "tok_span": [49, 54]
      },
      {
        "name": "( AP24534",
        "ent_type": "drug",
        "char_span": [119, 128],
        "tok_span": [28, 33]
      }
    ],
    "relation_list": [
      {
        "subject": "the T315I",
        "object": "inhibitor ponatinib",
        "sbj_char_span": [218, 227],
        "obj_char_span": [99, 118],
        "rel_type": "response",
        "sbj_tok_span": [49, 54],
        "obj_tok_span": [23, 28]
      },
      {
        "subject": "the T315I",
        "object": "( AP24534",
        "sbj_char_span": [218, 227],
        "obj_char_span": [119, 128],
        "rel_type": "response",
        "sbj_tok_span": [49, 54],
        "obj_tok_span": [28, 33]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Ponatinib is a potent BCR-ABL inhibitor with activity against the T315I mutation.",
    "entity_list": [
      {
        "name": "Ponatinib",
        "ent_type": "drug",
        "char_span": [0, 9],
        "tok_span": [0, 2]
      },
      {
        "name": "T315I",
        "ent_type": "variant",
        "char_span": [66, 71],
        "tok_span": [14, 18]
      }
    ],
    "relation_list": [
      {
        "subject": "T315I",
        "object": "Ponatinib",
        "sbj_char_span": [66, 71],
        "obj_char_span": [0, 9],
        "rel_type": "response",
        "sbj_tok_span": [14, 18],
        "obj_tok_span": [0, 2]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Notably , the T315I Bcr-Abl mutation does not respond to any approved TKI in vitro or clinically , except ponatinib which was approved by US FDA more recently .",
    "entity_list": [
      {
        "name": "ponatinib",
        "ent_type": "drug",
        "char_span": [106, 115],
        "tok_span": [27, 31]
      },
      {
        "name": "T315I",
        "ent_type": "variant",
        "char_span": [14, 19],
        "tok_span": [3, 7]
      }
    ],
    "relation_list": [
      {
        "subject": "T315I",
        "object": "ponatinib",
        "sbj_char_span": [14, 19],
        "obj_char_span": [106, 115],
        "rel_type": "response",
        "sbj_tok_span": [3, 7],
        "obj_tok_span": [27, 31]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "The single-arm , phase 2 Ponatinib Ph+ ALL and CML Evaluation (PACE) trial was conducted in 397 patients with refractory CML in CP , AP , or BP , or Ph+ ALL , resistant or intolerant to dasatinib or nilotinib , or with the resistant T315I mutation .",
    "entity_list": [
      {
        "name": "Ponatinib",
        "ent_type": "drug",
        "char_span": [25, 34],
        "tok_span": [7, 9]
      },
      {
        "name": "T315I",
        "ent_type": "variant",
        "char_span": [233, 238],
        "tok_span": [59, 63]
      }
    ],
    "relation_list": [
      {
        "subject": "T315I",
        "object": "Ponatinib",
        "sbj_char_span": [233, 238],
        "obj_char_span": [25, 34],
        "rel_type": "response",
        "sbj_tok_span": [59, 63],
        "obj_tok_span": [7, 9]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "More recently , a pan-BCR-ABL inhibitor TKI ( ponatinib ) was shown to be active against the T315I mutation .",
    "entity_list": [
      {
        "name": "ponatinib",
        "ent_type": "drug",
        "char_span": [46, 55],
        "tok_span": [14, 18]
      },
      {
        "name": "T315I",
        "ent_type": "variant",
        "char_span": [93, 98],
        "tok_span": [26, 30]
      }
    ],
    "relation_list": [
      {
        "subject": "T315I",
        "object": "ponatinib",
        "sbj_char_span": [93, 98],
        "obj_char_span": [46, 55],
        "rel_type": "response",
        "sbj_tok_span": [26, 30],
        "obj_tok_span": [14, 18]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "The FGFR tyrosine kinase inhibitors ( TKI ) dovitinib and NVP-BGJ398 are currently in clinical development and the FGFR TKI ponatinib , was recently approved by the FDA for use in treating T315I mutant chronic myelogenous leukemia .",
    "entity_list": [
      {
        "name": "ponatinib",
        "ent_type": "drug",
        "char_span": [124, 133],
        "tok_span": [33, 37]
      },
      {
        "name": "T315I",
        "ent_type": "variant",
        "char_span": [189, 194],
        "tok_span": [48, 52]
      }
    ],
    "relation_list": [
      {
        "subject": "T315I",
        "object": "ponatinib",
        "sbj_char_span": [189, 194],
        "obj_char_span": [124, 133],
        "rel_type": "response",
        "sbj_tok_span": [48, 52],
        "obj_tok_span": [33, 37]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Patient Mutation KIT inhibitor % RECIST Best response LDH × ULN baseline/best response PET response CNS relapse/progression 1 21 bp dup exon 11 Imatinib 60 PR1.1/0.8 Yes Yes 2 K642E exon 13 Imatinib 35 PR1.5/1.25 Yes No 3 L576P exon 11 Imatinib 42 PDa 12.5/1.2 NA Yes 4 D820Y exon 17 Sorafenib 27 SD 2.8/1.3 NA Yes",
    "entity_list": [
      {
        "name": "11 Imatinib",
        "ent_type": "drug",
        "char_span": [141, 152],
        "tok_span": [30, 33]
      },
      {
        "name": "3 L576P",
        "ent_type": "variant",
        "char_span": [220, 227],
        "tok_span": [64, 69]
      },
      {
        "name": "13 Imatinib",
        "ent_type": "drug",
        "char_span": [187, 198],
        "tok_span": [50, 53]
      },
      {
        "name": "11 Imatinib",
        "ent_type": "drug",
        "char_span": [233, 244],
        "tok_span": [70, 73]
      },
      {
        "name": "4 D820Y",
        "ent_type": "variant",
        "char_span": [268, 275],
        "tok_span": [85, 90]
      }
    ],
    "relation_list": [
      {
        "subject": "3 L576P",
        "object": "11 Imatinib",
        "sbj_char_span": [220, 227],
        "obj_char_span": [141, 152],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [64, 69],
        "obj_tok_span": [30, 33]
      },
      {
        "subject": "3 L576P",
        "object": "13 Imatinib",
        "sbj_char_span": [220, 227],
        "obj_char_span": [187, 198],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [64, 69],
        "obj_tok_span": [50, 53]
      },
      {
        "subject": "3 L576P",
        "object": "11 Imatinib",
        "sbj_char_span": [220, 227],
        "obj_char_span": [233, 244],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [64, 69],
        "obj_tok_span": [70, 73]
      },
      {
        "subject": "4 D820Y",
        "object": "11 Imatinib",
        "sbj_char_span": [268, 275],
        "obj_char_span": [141, 152],
        "rel_type": "response",
        "sbj_tok_span": [85, 90],
        "obj_tok_span": [30, 33]
      },
      {
        "subject": "4 D820Y",
        "object": "13 Imatinib",
        "sbj_char_span": [268, 275],
        "obj_char_span": [187, 198],
        "rel_type": "response",
        "sbj_tok_span": [85, 90],
        "obj_tok_span": [50, 53]
      },
      {
        "subject": "4 D820Y",
        "object": "11 Imatinib",
        "sbj_char_span": [268, 275],
        "obj_char_span": [233, 244],
        "rel_type": "response",
        "sbj_tok_span": [85, 90],
        "obj_tok_span": [70, 73]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "TP53 : Not done Yes PR 26.1 erlotinib , cetuximab PD1 5 Adenocarcinoma L858R ( exon 21 ) , G873E ( exon 21 ) Sensitive , Sensitive PIK3CA : E542K ( exon 9 )",
    "entity_list": [
      {
        "name": "cetuximab",
        "ent_type": "drug",
        "char_span": [40, 49],
        "tok_span": [15, 19]
      },
      {
        "name": "E542K",
        "ent_type": "variant",
        "char_span": [140, 145],
        "tok_span": [51, 55]
      }
    ],
    "relation_list": [
      {
        "subject": "E542K",
        "object": "cetuximab",
        "sbj_char_span": [140, 145],
        "obj_char_span": [40, 49],
        "rel_type": "resistance or non-response",
        "sbj_tok_span": [51, 55],
        "obj_tok_span": [15, 19]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "The failure to potently inhibit the D816V mutation is a feature of Kit inhibitors in the clinic , with the exception for dasatinib , which binds the `` DFG in '' , or activated form , of the kinase .",
    "entity_list": [
      {
        "name": "dasatinib",
        "ent_type": "drug",
        "char_span": [121, 130],
        "tok_span": [26, 28]
      },
      {
        "name": "D816V",
        "ent_type": "variant",
        "char_span": [36, 41],
        "tok_span": [7, 11]
      }
    ],
    "relation_list": [
      {
        "subject": "D816V",
        "object": "dasatinib",
        "sbj_char_span": [36, 41],
        "obj_char_span": [121, 130],
        "rel_type": "response",
        "sbj_tok_span": [7, 11],
        "obj_tok_span": [26, 28]
      }
    ],
    "umls_entity_list": []
  },
  {
    "text": "Intra-tumor heterogeneity caused by crizotinib resistance results from the L1196M gatekeeper ALK mutation , and other ALK secondary C1156Y mutations co-existed in malignant pleural effusion of a patient who acquired crizotinib resistance .",
    "entity_list": [
      {
        "name": "crizotinib",
        "ent_type": "drug",
        "char_span": [36, 46],
        "tok_span": [6, 10]
      },
      {
        "name": "L1196M",
        "ent_type": "variant",
        "char_span": [75, 81],
        "tok_span": [14, 18]
      },
      {
        "name": "crizotinib",
        "ent_type": "drug",
        "char_span": [216, 226],
        "tok_span": [47, 51]
      },
      {
        "name": "C1156Y",
        "ent_type": "variant",
        "char_span": [132, 138],
        "tok_span": [30, 34]
      }
    ],
    "relation_list": [
      {
        "subject": "L1196M",
        "object": "crizotinib",
        "sbj_char_span": [75, 81],
        "obj_char_span": [36, 46],
        "rel_type": "resistance",
        "sbj_tok_span": [14, 18],
        "obj_tok_span": [6, 10]
      },
      {
        "subject": "L1196M",
        "object": "crizotinib",
        "sbj_char_span": [75, 81],
        "obj_char_span": [216, 226],
        "rel_type": "resistance",
        "sbj_tok_span": [14, 18],
        "obj_tok_span": [47, 51]
      },
      {
        "subject": "C1156Y",
        "object": "crizotinib",
        "sbj_char_span": [132, 138],
        "obj_char_span": [36, 46],
        "rel_type": "resistance",
        "sbj_tok_span": [30, 34],
        "obj_tok_span": [6, 10]
      },
      {
        "subject": "C1156Y",
        "object": "crizotinib",
        "sbj_char_span": [132, 138],
        "obj_char_span": [216, 226],
        "rel_type": "resistance",
        "sbj_tok_span": [30, 34],
        "obj_tok_span": [47, 51]
      }
    ],
    "umls_entity_list": []
  }
]
